Podcasts about semaglutide

Thinking about trying a GLP-1 but not sure if you need a full dose? What exactly is microdosing, and does it really work? In this episode, I'm joined by Dr. Tyna Moore to talk about GLP-1s, microdosing, weight loss, muscle loss, menopause, hormone replacement therapy, and what's next for peptide therapy.

GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro have reshaped the weight-loss landscape almost overnight — but the way they're often prescribed leaves people under-fueled, losing muscle, and going it alone. In this episode of The Coaching Lab, host Leigh Baker sits down with National Board Certified Health & Wellness Coach Erin Chain and triple-board-certified physician Dr. Sheri Poznanovic of Optin Health & Nutrition to unpack what's really happening in the GLP-1 era — and where health and wellness coaching fits into the care plan.Together they explore why so many people on GLP-1s aren't eating or hydrating enough, how rapid weight loss can mask dangerous muscle mass loss, and why a "prescribe-and-disappear" model falls short. Dr. Poznanovic explains the multidisciplinary approach the Obesity Medicine Association recommends — combining medication, nutrition, body composition testing, VO2 max assessment, and coaching — while Erin shares real-world stories of clients navigating low energy, food noise, protein gaps, medication interactions, and the stigma of being on a GLP-1.Whether you're a coach, a clinician, an employer weighing GLP-1 coverage, or someone considering these medications yourself, this conversation offers a grounded, human look at doing weight loss in a way that protects strength, health span, and quality of life — not just the number on the scale.In this episode: • Why coaching alongside a GLP-1 changes outcomes • The under-eating and muscle-loss risks no one warns you about • Protein targets, carbs, and why "anti-carb" advice backfires • Body composition and VO2 max testing in weight management • Medication interactions as you lose weight • Navigating stigma and the joy of food • What employers and coaches should know before adding GLP-1sCoaches: Explore CE credits at catalystcoachinginstitute.com Employers: Learn about Catalyst Coaching's GLP-Whole offering — results@catalystcoaching360.com Join us this fall at the Rocky Mountain Coaching Retreat & Symposium: catalystcoachinginstitute.com/retreatInfo re earning your health & wellness coaching certification, annual Rocky Mountain Coaching Retreat & Symposium & more via https://www.catalystcoachinginstitute.com/ Best-in-class coaching for Employers, EAPs & wellness providers https://catalystcoaching360.com/Tap into the home of the (freely available) Not Done Yet! articles on unlocking life's 2nd half here.YouTube Coaching Channel https://www.youtube.com/c/CoachingChannelContact us: Results@CatalystCoaching360.comTwitter: @Catalyst2ThriveWebsite: CatalystCoaching360.comIf you are a current or future health & wellness coach, please check out our Health & Wellness Coaching Community on Facebook: https://www.facebook.com/groups/278207545599218.  This is a wonderful group if you are looking for encouragement, ideas, resources and more. 

Semaglutide, tirzepatide and retatrutide are often spoken about as though they are simply different versions of the same thing. They are not—and Kim Constable's personal experience with each one was very different. In this episode, Kim moves beyond receptor science and shares what exploring all three compounds was actually like for her: the benefits she noticed, the side effects she experienced, the results that surprised her and which option she personally preferred. Kim's interest in GLP-1s originally extended far beyond weight loss. As she moved further into menopause, she was struggling with persistent gluteal tendinopathy, joint pain, digestive discomfort, bloating, morning headaches, brain fog, broken sleep and repeated nighttime bathroom trips. Foods she had eaten comfortably for years—including beans, lentils and cruciferous vegetables—had become increasingly difficult to tolerate. After hearing GLP-1s discussed in relation to inflammation, digestion, sleep and metabolic health, Kim began exploring semaglutide. She later tried tirzepatide and retatrutide, allowing her to compare her personal response to all three. The compounds target different combinations of pathways: • Semaglutide primarily targets GLP-1 • Tirzepatide targets GLP-1 and GIP • Retatrutide targets GLP-1, GIP and glucagon Kim explains why those differences matter and why a compound that feels transformative for one person may feel far less effective—or create more unwanted effects—for another. Inside this episode: • Why Kim first became interested in GLP-1s during menopause • The difference between semaglutide, tirzepatide and retatrutide • Why more receptor activity does not automatically mean better results • Kim's personal experiences with appetite and food noise • The differences she noticed in inflammation and physical pain • Changes she observed in digestion, headaches, brain fog and sleep • How each experience affected fat loss and weight maintenance • Why she initially felt hesitant to admit that easier fat loss appealed to her • The judgment surrounding GLP use • Fatigue, headaches and digestive slowing • An unexpected herpes flare-up pattern Kim noticed while taking semaglutide • Why anecdotal observations do not prove clinical causation • The benefits that felt meaningful to Kim and the effects that did not • Which of the three she personally preferred • Why another person's experience or dose should never become your protocol This episode is not intended to tell listeners which compound they should choose. It is a candid account of Kim's individual experience with three different compounds and why she believes the decision is far more nuanced than simply asking which one is “strongest.” This episode contains candid discussion of genital herpes, digestive symptoms and medication side effects. Kim's experience is personal. Nothing discussed should be treated as proof that another person will experience the same benefits, risks or side effects. This podcast is for educational and informational purposes only. Kim is not a doctor or licensed medical practitioner. Nothing in this episode should be interpreted as medical advice, a diagnosis, prescribing guidance or instructions for purchasing, reconstituting, dosing or administering any compound. Always consult an appropriately qualified healthcare professional before beginning, stopping or changing any medication or treatment. Some compounds discussed may be prescription medicines or investigational products depending on jurisdiction and current regulatory status. ✨ Follow Kim Constable online for more real talk and daily motivation:

Primary care physicians Kate, Mark, Henry and Gary discuss 4 new studies that could change your practice: treatments for hyperemesis gravidarum, calcium and vitamin D to prevent falls and fractures in older adults, the first oral PCSK9 inhibitor, and oral semaglutide to treat dementia .The John Hickner Memorial fund at MSU: https://give.msu.edu/?sid=17374 Hyperemesis gravidarum treatments: https://pubmed.ncbi.nlm.nih.gov/41478546/ Supplementing with calcium or vitamin D: https://pubmed.ncbi.nlm.nih.gov/42161415/ Oral PCSK-9 enlicitide:  https://pubmed.ncbi.nlm.nih.gov/41879224/ Cochrane review of PCSK-9s: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011748.pub3/full Semaglutide for dementia: https://pubmed.ncbi.nlm.nih.gov/41865758/

Who on the team is on a GLP1 medication, why they started it and how's it going? An honest discussion. See omnystudio.com/listener for privacy information.

Imagine your spouse or significant other has been diagnosed with MS...shortly after you were diagnosed with stage IV colon cancer, and given just a 15% chance of survival. All of a sudden, the roles of patient and care partner are up for grabs -- and they change with almost daily frequency.  That's exactly the scenario my guest, Kathleen Silva, faced. Kathleen is joining me to discuss how she and her husband, Rick, survived and thrived amid that frightening chaos. (Spoiler alert -- no one died!)  We'll also tell you about an investigational drug that's the first to promise neuroprotection during an MS relapse. We're sharing study results that show people with MS who meet the medical criteria aren't jumping on the GLP-1 bandwagon. We'll provide compelling evidence for anyone with MS to quit smoking.  And we're breaking down the results of a study that analyzed mortality rates in cases where MS was listed as the underlying cause of death. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: When the roles of patient and care partner get turned upside down and inside out  :22 The FDA green lights clinical trials for an investigational drug that promises neuroprotection during an MS relapse   1:08 People living with MS who meet the medical criteria aren't jumping on the GLP-1 bandwagon   5:43 Study results provide startling evidence for quitting smoking if you're living with MS   8:34 In spite of highly effective DMTs, mortality rates for deaths in which MS is listed as the underlying cause are increasing  14:05 Kathleen Silva takes us through the harrowing time in her life when her husband, Rick, was diagnosed with MS shortly after she had been diagnosed with Stage 4 colon cancer and given just a 15% chance of surviving   19:23  Share this episode  35:12 Next week  36:31 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/468 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes at www.RealTalkMS.com STUDY: Use of Semaglutide and Tirzepatide Among People with Multiple Sclerosis https://journals.sagepub.com/doi/10.1177/13524585261442033 STUDY: Impact of Tobacco and Alcohol Consumption on Disease Progression and MRI In People With Multiple Sclerosis: Results of the Prospective Cohort Study NationMS https://journals.sagepub.com/doi/10.1177/17562864261464304 STUDY: Racial and Ethnic Trends and Comorbidity Patterns in Multiple Sclerosis Mortality https://www.neurology.org/doi/10.1212/WN9.0000000000000148 REGISTER: ECTRIMS Patient Community Day https://ectrimspatientcommunity.eu JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on X, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 468 Guest: Kathleen Silva Privacy Policy

What actually happens to a patient a year into real, supervised peptide therapy? In the final episode of our peptides series, Dr. Melissa Jones and host Jamie Preston close the loop on the story that opened this whole series — and get honest about what changed, what didn't, and what every provider and patient still needs to know. This episode goes beyond the science into the human side of the story: what it actually feels like when chronic pain resolves, when weight loss becomes life-changing rather than cosmetic, and when a skeptical clinician becomes one of the most passionate advocates in the building. Jamie also shares his own journey — turning 50, managing diabetes, and reaching his goal weight — as a real example of what supervised, responsible care can look like over time. In this episode, you'll hear: An update on the chronic pain patient from Episode 1 — where he is now, and what's kept his results sustainable What the actual clinical data shows about supervised BPC-157 therapy, and where its limits are Why GLP-1 success is about far more than the number on the scale — confidence, mobility, and mental health The advice Dr. Jones gives new providers who feel nervous bringing up peptides with patients The single biggest myth about peptides she wants to put to rest for good The three things every patient should understand before they ever start a peptide This is the episode that ties the whole series together — not as a sales pitch for peptides, but as a case for doing this the right way, with the right people, for the right reasons. It's the last episode in this run, but it won't be the last time we talk about this. www.YourHealth.Org

GLPs are everywhere right now — but do you actually know what they are or what they do? In this episode I break down the reality of GLP-1, what it is, how it works, and how your body already has the natural ability to activate it through a fasting-focused lifestyle. Whether you're considering the shot or just curious about how it all works, this episode gives you the full picture so you can make the best decision for your health and future. _____ Are you ready for real, compassionate support on your fasting journey from someone who has actually lived it? I've shed over 200 pounds through fasting and have maintained it through some of the hardest seasons of life. If you're tired of doing this alone, you don't have to anymore. Come find your people: The Fasting Support Club _____ REFERENCES Habener, J.F. (2004). The discovery of glucagon-like peptide 1. ScienceDirect — Molecular and Cellular Endocrinology. Retrieved from sciencedirect.com Mass General Brigham Newsroom. (2025). Joel Habener receives Breakthrough Prize in Life Sciences for contributions to GLP-1 medications. Retrieved from massgeneralbrigham.org Journal of Clinical Investigation. (2024). Joel Habener, Svetlana Mojsov, and Lotte Bjerre Knudsen awarded Lasker Prize for pioneering work on GLP-1. Retrieved from jci.org Eng, J. (1992). Discovery of exendin-4 in Gila monster venom. VA Medical Center, Bronx, NY. Referenced in: PlexusDx. (2026). History of GLP-1 drugs: Complete timeline from exenatide to tirzepatide. Retrieved from plexusdx.com Fella Health. (2025). What is GLP-1 lizard venom: Gila monster discovery to diabetes drugs. Retrieved from fellahealth.com U.S. Food and Drug Administration. (2005). Approval of exenatide (Byetta) for type 2 diabetes. FDA Drug Approval Database. Acosta, A. & Ghusn, W. (2023). Semaglutide shown to be effective for weight loss in multicentre, one-year real-world study. European Congress on Obesity (ECO2023). Presented by Precision Medicine for Obesity Program, Mayo Clinic. Retrieved from eurekalert.org Mayo Clinic Press. (2026). Health benefits of semaglutide beyond weight loss. Retrieved from mcpress.mayoclinic.org National Institutes of Health / NCBI. (2024). Patient perceptions of Ozempic (semaglutide) for weight loss: Mixed methods analysis of online medication reviews. Retrieved from ncbi.nlm.nih.gov National Institutes of Health / NCBI. (2024). Evaluation of pre-treatment assessment of semaglutide users: Balancing the benefits of weight loss vs. potential health consequences. Retrieved from ncbi.nlm.nih.gov Fung, J. (2016). The Obesity Code: Unlocking the secrets of weight loss. Greystone Books. Fung, J. (2025). The Hunger Code: Resetting your body's fat thermostat in the age of ultra-processed food. Greystone Books.

Have you experienced False Hope Syndrome? Without telling you exactly what that is, I'm going to let you know chances are good that you have. I have certainly done so in more than one area of my life! False Hope Syndrome runs rampant in relation to weight loss. Listen in, learn exactly what it is and how to keep yourself safe from falling into the disappointment associated with False Hope Syndrome as you move forward in losing and maintaining weight loss.The Weight Loss Winformation Podcast gives you essential psychological information to help you lose weight and more importantly, to help keep you at a healthy weight for your body! No matter how you are working to lose weight and no matter how much weight you want to lose, Weight Loss Winformation will keep you moving in a positive direction. Let's get started because well… Why Weight? (get it? Pun intended… )?Resources:·      BariAfterare: www.bariaftercare.com·      Connie Stapleton PhD website: www.conniestapletonphd.com·      BariAftercare website: https://www.conniestapletonphd.com/bariaftercare·      BariAftercare Facebook page (for members only): https://www.facebook.com/groups/BariAftercare·      Kevin Stephens: Your Bariatric Buddy   https://www.facebook.com/groups/yourbariatricbuddy/people·      Instagram: @ (Caleshia Haynes)·      Instagram: @therealbariboss (Tabitha Johnson)·      Instagram @drsusanmitchell (Dr. Susan Mitchell)·      Instagram: @lauraleepreston (Laura Preston)·      ProCare Vitamins (10% off with code ConnieStapleton)·      Rob DiMedio: https://www.busybariatrics.com/·      Dr. Joan Brugman: drjbrugman@outlook.com·      Dr. Nestor de la Cruz-Munoz on Linked In: https://www.linkedin.com/in/drdelacruzmunoz/From: How Much Weight Will You Lose After Bariatric Surgery? Nestor de la Cruz-Munoz MD, FACS, DABOMJuly 12, 2026 The Evidence Is Clear — And It's Not What Most Patients Expecto    The AACE/TOS/ASMBS guidelines are explicit: Very few preoperative factors are sufficiently predictive to give a precise individual weight loss number.This means the honest answer is not a number — it's a range.The Real Weight Loss Ranges by ProcedureThe most reliable metric is total weight loss percentage (TWL) — not excess weight loss.Sleeve Gastrectomy (SG)·       23–25% TWL at 1 year·       17–19% TWL at 5 years·       PCORnet (65,000+ patients): 18.8% TWL at 5 yearsRoux‑en‑Y Gastric Bypass (RYGB)·       28–31% TWL at 1 year·       21–26% TWL at 5 years·       20–27% TWL at 10 years·       PCORnet: 25.5% TWL at 5 years·       SM‑BOSS RCT: 27.5% TWL at 10 yearsOne‑Anastomosis Gastric Bypass (OAGB)·       Highest early TWL·       Emerging evidence suggests greater long‑term durability than SG and RYGB·       Randomized TrialsBy‑Band‑Sleeve RCT (3‑year outcomes):·       RYGB: 26.8% TWL·       Sleeve: 19.4% TWL·       Band: 14.0% TWLWeight regain after cessation of medication for weight management: systematic review and meta-analysiso   West S, Scragg J, Aveyard P, Oke JL, Willis L, Haffner SJP, Knight H, Wang D, Morrow S, Heath L, Jebb SA, Koutoukidis DA. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026 Jan 7;392:e085304. doi: 10.1136/bmj-2025-085304. PMID: 41500720; PMCID: PMC12776922.o   https://pubmed.ncbi.nlm.nih.gov/41500720/·       The primary anti-obesity medications (AOMs) highlighted in this high-level study are newer incretin mimetics, specifically:o   Semaglutide (a GLP-1 receptor agonist)o   Tirzepatide (a GIP/GLP-1 receptor co-agonist)The Rebound Effect: High-Level EvidenceThis January 2026 systematic review and meta-analysis published in The BMJ synthesized data from 37 studies involving 9,341 participants, providing robust, high-level clinical evidence on what happens after stopping these medications:·       Rapid Return to Baseline: On average, patients return to their baseline weight within 1.7 years after stopping any weight management medication.·       Accelerated Regain for GLP-1/GIP Drugs: For those stopping semaglutide or tirzepatide, the rebound is even faster—returning to baseline weight in just 1.5 years.·       Faster than Behavioral Programs: The rate of weight regain after medication cessation is significantly faster than the regain observed after finishing behavioral weight management programs.·       Reversal of Health Benefits: Stopping these therapies also rapidly reverses their positive, beneficial effects on cardiometabolic markers.·       These findings emphasize that using these medications short-term without a more comprehensive, long-term approach to weight management leads to a rapid reversal of both weight loss and cardiometabolic improvements, and this is the real benefit we can offer to our patients: a long-term plan that can and should be updated on the course of their chronic disease and its natural course. Nothing in obesity treatment should be absolutely static.·      How to overcome past dieting failures. By Kristen A. Carter MSo   https://www.psychologytoday.com/us/blog/health-and-human-nature/202103/false-hope-syndrome-reveals-big-problem-dieting·      Getting Real: Warning Signs of False Hope Syndrome. by Dan J. Tomasulo PhD., TEP, MFA, MAPPo   https://www.psychologytoday.com/us/blog/the-healing-crowd/202209/getting-real-warning-signs-of-false-hope-syndrome·      Expected Weight Loss From Gastric Bypass – Calculatoro   https://www.obesitycoverage.com/weight-loss-surgeries/gastric-bypass/how-much-can-i-expect-to-lose·      Expected Weight Loss (after Sleeve)o   https://www.obesitycoverage.com/gastric-sleeve-reference-manual/

Two experts in obesity medicine discuss the latest advances in obesity care, including: Current data for incretin-based therapies Beyond the scale—individualizing OMM selection based on weight-related comorbidities and cardiometabolic risk Common contraindications and warnings associated with certain OMMs Shared decision-making strategies to inform treatment selection. [JF1]Added this to the episode notes to maybe help with the posttest  Presenters Amy Butts, PA-C, DFAAPA, BC-ADM, CDCES Endocrine Physician Associate WVU Medicine Wheeling Hospital Immediate Past President of American Society of Endocrine Physician Associates Wellsburg, West Virginia Nicholas Pennings, DO Professor of Family Medicine Campbell University School of Osteopathic Medicine Director of Clinical Education Obesity Medicine Association Buies Creek, North Carolina Link to full program:https://bit.ly/4v7eIY4 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Multispecialty Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What if the peptide you just ordered online isn't wrong — it's just wrong for you? In Episode 2 of our peptides series, clinical pharmacist Dr. Melissa Jones takes us inside the actual decision-making process providers use to match a peptide to a patient, and why skipping that process is how people end up wasting money, or worse, hurting themselves. Host Jamie Preston and Dr. Jones dig into the real science: what a peptide is, how peptides signal the body, and why a healthy foundation — hormones and gut health — has to come before any peptide is even considered. From there, they cover the wide menu of options (tissue repair, skin and hair, sexual health, growth hormone support, metabolic health, sleep and stress) and what it actually means to “stack” or “cycle” peptides responsibly. In this episode, you'll hear: Why there isn't — and won't be — one peptide that does it all, and what that means for how providers build a plan How stacking and cycling actually work, and where cost becomes a real factor in the decision The difference between FDA-approved peptide uses (like Tesamorelin for visceral fat) and the anecdotal dosing happening across the wellness world The real danger in reconstituting and self-dosing peptides ordered online, explained in plain terms What responsible, supervised GLP-1 (Mounjaro, Ozempic, tirzepatide) therapy looks like — and what goes wrong with compounded, unregulated versions The specific list of patients who should avoid peptides or use extra caution, and why providers need to know it cold If you've ever wondered whether a peptide could actually help you — or wondered what your provider is really weighing before saying yes — this episode gives you the real answer, not the Instagram version. www.YourHealth.Org

This video reveals how your skin uses glutathione to defend itself, how Dr. Nayan Patel solved its delivery problem, and why his topical antioxidant serum was clinically shown to improve the appearance of fine lines, wrinkles, and skin tone in just 1 week.You'll also learn:The molecule (glutathione) behind clinically-backed wrinkle reduction in 7 daysWhy oxidative stress, not just low collagen, drives visible skin agingHow free radicals damage collagen, elastin, and skin toneWhy glutathione is the body's "master antioxidant" for skin protectionThe 4 barriers any skincare ingredient must survive to actually work (bioavailability)The delivery system breakthrough (RO-GSH) that finally makes topical glutathione effectiveHow to use the full glutathione skincare system (serum, copper peptides, vitamin C) for results in one weekTry Danger Creatine: https://dangercoffee.com/products/danger-creatineTry TrueDark glasses: https://truedark.comTry Danger Coffee: https://dangercoffee.com/discount/davetubeTry Suppgrade Labs: https://shopsuppgradelabs.com/Thank you to our sponsors!PredictiveMind™ | Get your Brain Pattern Mapping report at predictivemind.io/dave and use code DAVE for 10% off.Viome | Check it out at viome.com and use code 16DAVE for 16% off. It's time to stop guessing and start knowing your body.iRestore | Reverse hair loss at www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVETimestamps:00:00 - Intro00:19 - Anti-Aging Drug Screening01:43 - Protein Restriction & Aging03:36 - New Skin Injectable05:23 - Arts & Longevity07:30 - Biohacking Interventions Reviewed08:51 - Semaglutide & Aging Clocks09:29 - Closing TakeawaysConnect with Dave Asprey!Website: https://daveasprey.comTikTok: https://www.tiktok.com/@daveaspreyofficialInstagram: https://www.instagram.com/dave.asprey/Facebook: https://www.facebook.com/Daveaspreyofficial/X: https://x.com/daveaspreyYouTube: https://www.youtube.com/c/daveaspreybprThe Human Upgrade Podcast: https://www.instagram.com/TheHumanUpgradePodcast/ https://m.facebook.com/Thehumanupgrade/Dave Asprey's BEYOND Conference: https://beyondconference.com/Dave Asprey's New Book - Heavily Meditated: https://daveasprey.com/heavily-meditated/Dave's favorite supplements: https://www.shopsuppgradelabs.com/discount/DAVE15Upgrade Labs: https://upgradelabs.com40 Years of Zen: https://40yearsofzen.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Subtitle: A Nasal Spray Longevity Screen, Why Less Protein May Age You Better, Cadaver Skin Injectables, Art's Effect on Biological Age, and Which Anti-Aging Interventions Actually Move the Needle Nasal Spray Ingredient Emerges As Unexpected Longevity Candidate In Massive Drug Screen Researchers mapped 2,358 longevity-associated genes across the body's broader protein and signaling networks, then screened 6,442 approved drugs to see which ones nudged those aging pathways in a healthier direction. Oxymetazoline, the active ingredient in nasal sprays like Afrin, was among 21 standout candidates, with a predicted pathway running through the ACKR3 receptor and connecting to major aging proteins including NF-kB, TP53, and AKT1. Host Dave Asprey explains why this computational screen is a promising research lead rather than a protocol, and why chronic use of a vasoconstricting nasal spray carries real risks regardless of what a network analysis suggests. Sources: https://www.inc.com/lucia-auerbach/scientists-screened-6442-drugs-for-longevity-common-nasal-spray-emerged-as-a-surprising-candidate/91381000 https://www.sciencealert.com/medications-already-in-pharmacies-may-slow-aging-and-scientists-are-narrowing-them-down https://pmc.ncbi.nlm.nih.gov/articles/PMC12425021/ ~~ New Review Of 350+ Studies Asks Whether Less Protein Means Longer Life A review spanning more than 350 studies found that protein restriction consistently extended lifespan and improved metabolic health across mice, rats, flies, and fish, with smaller human studies showing improvements in body fat and fasting glucose even when total calorie intake rose. Researchers point to FGF21, a liver hormone that rises under protein or amino acid scarcity and boosts energy expenditure and glucose regulation, as a key mechanism. Host Dave Asprey breaks down why blanket protein advice fails older adults preserving muscle and highly active people just as badly as it fails everyone else, and why matching intake to actual biology beats maximizing protein at every meal. Sources: https://www.medicalnewstoday.com/articles/why-reducing-protein-intake-could-promote-healthy-aging-new-research https://time.com/article/2026/08/03/eat-less-protein-age-better-live-longer/ https://www.sciencedaily.com/releases/2026/08/260801042811.htm https://www.cell.com/cell-reports-blue/fulltext/S2949-8821(26)00079-9 https://pmc.ncbi.nlm.nih.gov/articles/PMC8991228/ https://www.eurekalert.org/news-releases/1137190 ~~ Processed Cadaver Skin Injectable Enters The Anti-Aging Market As Elravie Re2O A new injectable called Elravie Re2O, short for "return to your 20s," is made from donated human skin processed to remove living cells and most genetic material, leaving a collagen-rich extracellular matrix that gets injected into the face and neck as a biological scaffold rather than a simple filler. Human-derived tissue matrices already have a track record in burn and wound care, but this specific product is not yet FDA-approved and lacks comparative trial data against existing fillers. Host Dave Asprey separates legitimate regenerative medicine from a novel cosmetic product still waiting on long-term safety and consistency data. Sources: https://nypost.com/2026/07/21/health/the-hottest-new-anti-aging-treatment-cadaver-skin/ https://www.newsobserver.com/living/article316698211.html https://www.miamiherald.com/living/article316698295.html https://pmc.ncbi.nlm.nih.gov/articles/PMC12985180/ https://laboderm-skin.com/elravie-re2o-application/ ~~ UCL Study Finds Weekly Arts Engagement Tracks With Slower Epigenetic Aging A University College London study of more than 3,500 adults found that people who engaged weekly with arts and culture, including painting, music, museums, and theater, showed a roughly four percent slower pace of aging on the DunedinPACE clock and appeared about one biological year younger on PhenoAge, with the effect holding after adjusting for income, education, smoking, and physical activity. Benefits appeared whether people were actively creating art or simply attending performances and exhibits. Host Dave Asprey argues this expands what counts as a health input beyond molecules and devices, since novelty, meaning, and social connection influence the nervous system too. Sources: https://www.npr.org/2026/05/12/nx-s1-5818172/study-arts-slow-biological-aging https://www.news-medical.net/news/20260511/Regular-arts-engagement-may-help-slow-biological-aging-process.aspx https://studyfinds.com/arts-culture-may-slow-aging/ ~~ Review Of 41 Human Studies Ranks Which Interventions Actually Shift Epigenetic Clocks A review of 41 human studies testing interventions against newer-generation epigenetic clocks found favorable changes for exercise, caloric restriction, omega-3s, plant-rich diets, multivitamins, semaglutide, pitavastatin, and ketamine, while nicotinamide riboside, rapamycin, and senolytics showed no detected clock improvement in the studies reviewed. Semaglutide produced the strongest single result, slowing DunedinPACE by about nine percent in a trial of adults with HIV-associated fat redistribution, though a separate fatty liver study produced mixed outcomes. Host Dave Asprey explains why a strong mechanistic story does not guarantee a moved biomarker, and why clinical outcomes, functional measures, and safety data all matter alongside any single clock reading. Sources: https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2026.1836446/full https://pubmed.ncbi.nlm.nih.gov/42294499/ https://www.news-medical.net/news/20260616/Semaglutide-omega-3s-and-diet-shift-epigenetic-aging-clocks-in-human-studies.aspx https://www.nature.com/articles/s41514-026-00383-9 https://pmc.ncbi.nlm.nih.gov/articles/PMC12338914/ https://medicalxpress.com/news/2026-06-popular-glp-drug-biological-aging.html https://www.creativebiomart.net/blog/semaglutide-may-slow-epigenetic-aging-in-humans https://www.aging-us.com/article/202913/text https://superpower.com/guides/can-you-reverse-epigenetic-age https://www.nature.com/articles/d41586-026-01836-7 https://www.businessinsider.com/first-ever-reverse-aging-drug-was-just-injected-into-a-human-2026-6 ~~ This episode is designed for biohackers, longevity enthusiasts, and high-performance listeners who want mechanism-level insights into a computational drug-repurposing screen, the case for eating less protein, a new regenerative injectable made from human tissue, the biological effect of creative engagement, and a data-driven ranking of which longevity interventions actually move epigenetic clocks. Host Dave Asprey connects computational biology, nutrition science, regenerative medicine, and biomarker research into practical frameworks for evaluating what belongs in a real longevity protocol versus what belongs on a watch list. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: oxymetazoline longevity, drug repurposing screen aging, ACKR3 receptor aging pathway, protein restriction longevity, FGF21 hormone aging, low protein diet healthspan, cadaver skin injectable, Elravie Re2O, extracellular matrix regenerative medicine, anti-aging injectable 2026, arts engagement biological age, DunedinPACE epigenetic clock, PhenoAge biological age, epigenetic clock interventions, semaglutide epigenetic aging, rapamycin epigenetic clock, senolytics human trials, biological age testing, biohacking news 2026, Dave Asprey, The Human Upgrade Thank you to our sponsors! - KILLSwitch | If you're ready for the best sleep of your life, order now at https://www.switchsupplements.com/and use code DAVE for 20% off - Beyond Wonderland Conference | Oct 13 - 14, 2026. Get your ticket now at wonderlandconference.com. - iRestore | Reverse hair loss at www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVE Resources: • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Intro 00:19 – Anti-Aging Drug Screening 01:43 – Protein Restriction & Aging 03:36 – New Skin Injectable 05:23 – Arts & Longevity 07:30 – Biohacking Interventions Reviewed 08:51 – Semaglutide & Aging Clocks 09:29 – Closing Thoughts See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Could you please comment on the new study that finds protein restriction could slow aging?Considerations for protein intake across the lifespanMy bone mineral density has improved with strontium. Should I stop taking it?  What about vitamin K2?

Novo Nordisk has spent years warning patients, regulators, lawmakers, and courts about the risks of synthetic semaglutide. Now, as patents begin to expire and China's pharmaceutical industry becomes increasingly important, Novo may be staring at a very uncomfortable question: what happens if synthetic semaglutide suddenly makes sense when Novo is the one making it?In this week's episode of The Weekly Dose, I dig into Novo's long-running recombinant-versus-synthetic semaglutide argument, the lawsuits and FDA petitions built around it, and a clip from more than 16 months ago showing that we were covering this exact issue long before it became part of the mainstream conversation. Novo Warned Us About Synthetic Semaglutide_ Now This_.txtWe also break down Pfizer's decision to kill two clinical-stage obesity drugs, including an oral GLP-1 acquired through its $10 billion Metsera deal, the strange science behind GIP receptor antagonism, and why Pfizer's remaining obesity pipeline still deserves attention. Plus, Wall Street is looking at Eli Lilly's obesity-fueled rally and asking just how big this market can get.In this episode:00:00 Novo's synthetic semaglutide problem02:00 VoaFit sponsor message03:30 The 16-month-old On The Pen receipt05:00 Recombinant vs. synthetic semaglutide07:00 Novo's FDA, legal, and political strategy09:00 Pfizer kills two obesity drugs11:00 What happened to Metsera's oral pipeline?13:00 The GIP agonist vs. antagonist paradox15:00 Why China matters to Pfizer and Novo17:00 Could Novo eventually make synthetic semaglutide?18:30 What comes next for Lilly, Novo, and PfizerThe big question: If Novo Nordisk eventually launches its own synthetically manufactured semaglutide, does that change how you view the arguments it has made against compounded semaglutide over the last several years?Comment below. I want to know where you land.More obesity medicine news and analysis: OnThePen.comAll my links, socials, and resources: linktr.ee/manonthemounjaroThis episode is sponsored by VoaFit. Learn more at voafit.com/otp.#GLP1 #Semaglutide #Ozempic #Wegovy #NovoNordisk #CompoundedSemaglutide #ObesityMedicine #Pfizer #EliLilly #Mounjaro #Zepbound #Metsera

You've seen the ads. You've heard the buzz. But do you actually know what peptides are — or what they're doing inside your body? In this first episode of a three-part series, Jamie Preston sits down with Dr. Melissa Jones, a 25-year clinical pharmacist and VP at Your Health, to lay the foundation every patient and provider needs before entering the peptide conversation. Dr. Jones brings rare credibility to this space — she didn't come in as a believer, she came in as a scientist who was challenged to learn, and what she found changed how she practices. What you'll hear in this episode: Why insulin is a peptide — and why that means peptides have been in your medicine cabinet for years How BPC 157 and TB 500 work together to signal the body to heal — and the real patient stories behind that science Why GLP-1 medications like Mounjaro and Ozempic are peptides, and how they actually produce weight loss The difference between peptides and steroids (hint: one sends signals, one messes with your hormones) Why "research use only" labels are a red flag — and why compounding pharmacies matter more than you think What providers need to start asking patients right now Whether you're a patient who's been curious or a provider who's been hesitant, this episode gives you the grounded, evidence-informed starting point you've been looking for. Part two goes even deeper — but this is where it begins. www.YourHealth.Org

What if the real question isn't "Which peptide should I take?" but "Do I need one at all?"Peptides like Ozempic (GLP-1 medications), BPC-157, MOTS-c, CJC-1295, and other bioactive peptides have exploded in popularity for weight loss, fat burning, muscle recovery, longevity, metabolism, and anti-aging. But are they truly the best solution—or could they be masking the underlying problem?In this episode of Accelerated Health with Sara Banta, I break down the science behind today's most talked-about peptides, who may actually benefit from them, their potential risks and side effects, and why supporting your body's natural healing pathways may be just as important.If you're considering peptides—or you're simply curious whether these trending treatments are worth the hype—this is an episode you won't want to miss.Supplements Featured In This Episode:• Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Fast® https://www.acceleratedhealthproducts.com/products/accelerated-fast-supplement • Accelerated Ancient Salt® https://www.acceleratedhealthproducts.com/products/accelerated-ancient-salt-4-oz• Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care• Accelerated Methylene Blue® https://www.acceleratedhealthproducts.com/products/accelerated-methylene-blue-supplementNot sure what food to eat and avoid? This guide is for you.⬇️

You might think the win on a GLP-1 like Ozempic or Mounjaro is the number dropping on your scale, but I need you to ask a better question, not how much you're losing, but what kind. In some studies, 40 to 60% of the weight people lost on these drugs came from lean muscle, not fat, and that's a metabolic loss that costs you your strength and your ability to keep the weight off. These are the most powerful fat-loss tools we've ever had, but a tool without a protocol is just potential. Hit your protein and lift, or you're trading muscle for a number you'll spend years trying to earn back. CLICK HERE TO BECOME GARYS VIP!: https://bit.ly/4ai0Xwg Thank you to our partners A-GAME: “ULTIMATE15” FOR 15% OFF: http://bit.ly/4kek1ij AION: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD AIRES: "ULTIMATE20 " FOR 20% OFF: https://bit.ly/4a3Duze BAJA GOLD: "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa BODYHEALTH: “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV COLD LIFE: THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKpCYMBIOTIKA: "BRECKACYM30" FOR 30% OFF: https://bit.ly/4tjyluP GENETIC METHYLATION TEST (UK ONLY): https://bit.ly/48QJJrk GENETIC TEST (USA ONLY): ⁠https://bit.ly/3Yg1Uk9 GOPUFF: GET YOUR FAVORITE SNACK!: https://bit.ly/4obIFDC H2TABS: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg HEALF: 10% OFF YOUR ORDER: https://bit.ly/41HJg6S PEPTUAL: “TUH10” FOR 10% OFF: https://bit.ly/4mKxgcn SNOOZE: LET'S GET TO SLEEP!: https://bit.ly/4pt1T6V WHOOP: JOIN & GET 1 FREE MONTH!: https://bit.ly/3VQ0nzW Watch  the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8fo X: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps 00:00 - Intro of Show 00:22 - Weight loss vs fat loss 00:38 - What GLP-1 does in the body 01:02 - Semaglutide: the first generation 01:28 - Tirzepatide and the dual agonist 01:45 - Retatrutide and 24.2% body weight loss 02:20 - Why each added receptor works 02:38 - The hidden cost: protecting lean muscle 03:05 - 60% of weight loss from muscle 03:35 - The two-part fix: protein and training 04:05 - Protein targets and leucine-rich sources 04:30 - Resistance training and compound lifts 05:00 - Use the medication, do the work Disclaimer: This podcast is for informational purposes only and does not provide medical advice. It is not intended for diagnosing or treating any health condition. Always consult a licensed healthcare professional before making health or wellness decisions.  Gary Brecka is the owner of Ultimate Human, LLC which operates The Ultimate Human podcast and promotes certain third-party products used by Gary Brecka in his personal health and wellness protocols and daily life and for which Ultimate Human LLC and / or Gary Brecka directly or indirectly holds an economic interest or receives compensation.  Accordingly, statements made by Gary Brecka and others (including on The Ultimate Human podcast) may be considered promotional in nature. Learn more about your ad choices. Visit megaphone.fm/adchoices

CardioNerds (Drs. Apoorva Gangavelli, Jenna Skowronski, and Hannah Every) discuss the continuum of prevention and heart failure with Drs. Anu Lala and Martha Gulati. Grounded in a clinical case of a 55-year-old woman with uncontrolled hypertension, type 2 diabetes, and obesity who is on the trajectory toward heart failure, this episode unpacks a paradigm-shifting framework from a joint HFSA/ASPC Scientific Statement. The discussion explores how prevention should not be siloed from heart failure management but rather integrated across a patient’s lifespan—from primary prevention in at-risk individuals, to secondary prevention in those with established heart failure, to tertiary prevention in patients with advanced therapies such as LVADs and heart transplantation. The experts highlight the importance of aggressive risk factor management, biomarker-guided screening, the AHA’s Life’s Essential 8, and the need for multidisciplinary collaboration and systems-level change to shift heart failure care from reactive to proactive. Audio editing for this episode was performed by CardioNerds Intern, Dr. Julia Marques Fernandes. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Systemic inflammatory diseases are associated with an elevated CVD risk that has significant implications for early detection, risk Heart failure prevention is a continuum, not a checkpoint. Prevention applies at every stage—from at-risk (Stage A) through advanced/post-transplant care—and every clinical encounter is an opportunity to intervene. The AHA’s Life’s Essential 8 (diet, physical activity, nicotine exposure, sleep, BMI, blood lipids, blood glucose, blood pressure) forms the foundation at every stage. Hypertension carries the highest population-attributable risk for heart failure of any modifiable risk factor. In the Framingham Heart Study, 91% of patients with newly diagnosed HF had pre-existing hypertension. The SPRINT trial demonstrated a 38% reduction in HF incidence with intensive blood pressure targets (30 ng/L or NT-proBNP >125 ng/L) identify individuals at heightened risk for progression to symptomatic HF. The ACC/AHA/HFSA guidelines give a Class IIa recommendation for natriuretic peptide screening in at-risk patients. Urine albumin-to-creatinine ratio (UACR) is an underutilized screening tool that provides additional insight into CKM risk. The heart failure label does not close the prevention window—it accentuates it. Secondary prevention through GDMT optimization (quadruple therapy in HFrEF) and continued risk factor management remains critical. Tertiary prevention extends to post-LVAD and post-transplant patients, where hypertension, diabetes, obesity, and CKD management remain essential to long-term outcomes. Show notes For a comprehensive review, please review the full HFSA/ASPC Joint Scientific Statement: Lala A, Beavers C, Blumer V, et al. The Continuum of Prevention and Heart Failure in Cardiovascular Medicine. J Card Fail. 2026;32:75-105. doi:10.1016/j.cardfail.2025.06.013 1. What is the “continuum of prevention” framework, and how does it differ from traditional approaches to heart failure prevention? Historically, prevention and heart failure management have been treated as separate disciplines—primary prevention handled by preventive cardiologists and treatment managed by heart failure specialists. This joint HFSA/ASPC Scientific Statement reframes prevention as a dynamic, continuous process that spans a patient’s entire lifespan, regardless of HF stage or ejection fraction. The framework maps onto the ACC/AHA HF staging system: Primary prevention targets Stage A (“at risk”) and Stage B (“pre-HF”) patients to reduce the burden of incident HF. Secondary prevention targets Stage C (symptomatic) and Stage D (advanced) patients to reduce the impact of established HF through GDMT optimization and ongoing risk factor management. Tertiary prevention encompasses risk factor management in patients with LVADs or heart transplants—populations where hypertension, diabetes, and obesity still drive outcomes. The Central Figure of the statement illustrates that Life’s Essential 8 (blood pressure and lipid control, diabetes management, exercise, sleep, smoking cessation, weight management, and diet/nutrition counseling) forms the foundation at every stage, with pharmacologic and device-based therapies layered on top as disease progresses (Figure) 2. How do traditional risk factors drive heart failure, and what should clinicians prioritize? Hypertension carries the greatest population-attributable risk for HF. In the Framingham Heart Study (N=5,143), HTN was associated with a 2- to 3-fold increased risk of HF, with a population-attributable risk of 39% in men and 59% in women. The SPRINT trial showed a 38% reduction in HF incidence and 25% reduction in the primary composite outcome with intensive BP targets (30 ng/L or NT-proBNP >125 ng/L) are associated with heightened risk for progression to symptomatic HF. In the ARIC study, incorporating NT-proBNP reclassified 20% of older adults without HF into Stage B. Factors that affect interpretation include age, sex, obesity (lower values), and CKD (higher values). High-sensitivity cardiac troponin (hs-cTn): Concentrations above the 99th percentile are now included in the definition of Stage B HF. Troponin testing may complement natriuretic peptides, particularly when BNP/NT-proBNP values are ambiguous. Risk scores: The PCP-HF equation predicts 10-year HF risk using traditional risk factors plus QRS duration. The AHA PREVENT score incorporates HF risk calculation and includes markers of kidney function (albuminuria, eGFR), though it may underestimate risk in men and Black adults. The CKM syndrome staging framework (Stages 0–4) provides a holistic approach to assessing systemic cardiovascular-kidney-metabolic risk. 4. What are the key nontraditional risk factors and cross-cutting themes in heart failure prevention? Genetics: Pathogenic cardiomyopathy variants exist in ~1 in 200 individuals in the general population. The HFSA and ACMG recommend cascade testing to identify at-risk family members. Polygenic risk scores for dilated cardiomyopathy show a 3.8-fold risk for DCM in the top 10th percentile compared with the median. Sex-specific considerations: Women have 2.8 times the odds of developing HFpEF, while men have similarly increased odds of HFrEF. A complete obstetric/gynecologic history is essential—preeclampsia is associated with a 4-fold increased risk of HF. Peripartum cardiomyopathy requires intentional screening in high-risk populations. Cardiotoxic exposures: Clinicians should be aware of medications that cause direct myocardial toxicity (e.g., anthracyclines, trastuzumab, tyrosine kinase inhibitors). A team-based approach with pharmacists can help optimize medication selection and risk factor modification. Social determinants of health: Environmental exposures (air pollution, arsenic, lead, cadmium), food insecurity, financial instability, and limited healthcare access contribute to HF risk and progression. Equity-focused, risk-based prevention strategies are needed. Psychological health: Depression is common in HF and independently associated with worse outcomes. Screening with brief questionnaires (e.g., PHQ-2) is recommended. Meditation, spirituality, and holistic wellness approaches remain underutilized. 5. What systems-level and policy changes are needed to move the needle on heart failure prevention? Multidisciplinary HF prevention clinics that bring together preventive cardiologists, HF specialists, endocrinologists, nephrologists, dietitians, pharmacists, exercise physiologists, and genetic counselors are advocated by the statement. EHR-embedded risk stratification could proactively flag patients on a trajectory toward HF—analogous to sepsis alerts or fall risk flags—enabling earlier intervention, particularly for patients who may not reach a cardiologist. Cardiac rehabilitation remains underutilized, particularly in HFrEF (Class 2b recommendation) and HFpEF (not yet covered by Medicare). The HF-ACTION trial showed quality-of-life benefits, and the REHAB-HF trial showed particular benefit in older patients with HFpEF. Policy priorities include expanding insurance coverage for preventive screening and novel therapies (SGLT2i, GLP-1 RAs, nsMRAs), reducing clinical inertia through team-based care models with closer follow-up intervals, and ensuring equitable access to evidence-based therapies across diverse populations. Digital health and AI hold promise for personalized risk prediction, remote monitoring (e.g., wearable devices, implantable PA pressure monitors), and virtual cardiac rehabilitation to overcome access barriers. Figure  Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013) References Key references are bolded. Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013 Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022;146(5):e18-e43. doi:10.1161/CIR.0000000000001078 SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939 Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557-1562. doi:10.1001/jama.1996.03530440037034 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997. doi:10.1001/jama.288.23.2981 Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153. doi:10.1056/NEJM200001203420301 Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720 Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286 Filippatos G, Anker SD, Agarwal R, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022;145(6):437-447. doi:10.1161/CIRCULATIONAHA.121.057983 Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107 Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773-786. doi:10.1016/S0140-6736(24)01498-3  Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963 Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148(20):1636-1664. doi:10.1161/CIR.0000000000001175 Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024;149(6):430-449. doi:10.1161/CIRCULATIONAHA.123.067626 Khan SS, Ning H, Shah SJ, et al. 10-year risk equations for incident heart failure in the general population. J Am Coll Cardiol. 2019;73(19):2388-2397. doi:10.1016/j.jacc.2019.02.057 Bozkurt B, Fonarow GC, Goldberg LR, et al. Cardiac rehabilitation for patients with heart failure: JACC expert panel. J Am Coll Cardiol. 2021;77(11):1454-1469. doi:10.1016/j.jacc.2021.01.030 Packer M. Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation. 2018;137(15):1614-1631. doi:10.1161/CIRCULATIONAHA.117.032474 Lala A, Tayal U, Hamo CE, et al. Sex differences in heart failure. J Card Fail. 2022;28(3):477-498. doi:10.1016/j.cardfail.2021.10.006 Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure. Eur J Heart Fail. 2021;23(3):352-380. doi:10.1002/ejhf.2115 Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy—a Heart Failure Society of America practice guideline. J Card Fail. 2018;24(5):281-302. doi:10.1016/j.cardfail.2018.03.004 Levine GN, Cohen BE, Commodore-Mensah Y, et al. Psychological health, well-being, and the mind-heart-body connection: a scientific statement from the American Heart Association. Circulation. 2021;143(10):e763-e783. doi:10.1161/CIR.0000000000000947 Ezekowitz JA, Colin-Ramirez E, Ross H, et al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet. 2022;399(10333):1391-1400. doi:10.1016/S0140-6736(22)00369-5

¿Has escuchado maravillas sobre medicamentos como Ozempic, Wegovy o Mounjaro, pero nadie te habla de las constantes náuseas y el malestar estomacal? La realidad clínica es que una gran parte de los pacientes abandonan estos tratamientos para la obesidad simplemente porque los efectos secundarios arruinan su calidad de vida. Pero la ciencia médica está a punto de dar un salto monumental. En este episodio, descubriremos a la AMILINA, una hormona producida por tu páncreas que está demostrando resultados asombrosos en ensayos clínicos: pérdida de peso significativa sin los severos vómitos ni malestares intestinales de los fármacos actuales. En este episodio aprenderás: → Cómo tu páncreas libera dos hormonas cada vez que comes. → Cómo la amilina bloquea el freno metabólico que hace que recuperes el peso perdido. → Cómo dos equipos de investigadores resolvieron el mismo problema químico de formas distintas. → Cómo la combinación CagriSema alcanza una reducción significativa del peso corporal. → Por qué la amilina resensibiliza tu cerebro a la leptina, algo que la semaglutida no logra.   Mi nombre es Dr. Mauricio González, médico internista y especialista en endocrinología en formación. Aquí comparto información basada en evidencia para que tomes decisiones de salud sin mitos ni marketing engañoso. Suscríbete a mi boletín informativo en: www.drmauriciogonzalez.com/   ⚠️ Este podcast tiene fines exclusivamente educativos e informativos y no constituye asesoramiento médico, diagnóstico ni tratamiento personalizado. Los medicamentos que se discuten en este episodio se encuentran en fase de investigación y no cuentan con aprobación de la FDA. Consulta siempre a tu médico o a un profesional de la salud calificado antes de cambiar tu régimen de tratamiento.   ¡Sigamos la conversación en redes sociales! Instagram

Dr. Mike Hart welcomes Ksenia Petrushkina back for a wide-ranging conversation about using hormones, GLP-1 medications, and peptides more thoughtfully. They explore why lower, individualized doses of tirzepatide may improve tolerability, which blood markers should be monitored during treatment, and how progesterone may support sleep through its effects on GABA. They also discuss women's hormone replacement therapy, personalized testosterone dosing, TRT and fertility, thyroid treatment, low-dose naltrexone, and the difference between evidence-based peptide use and exaggerated online claims. Ksenia Petrushkina is a clinician whose work focuses on hormone optimization, peptide therapy, metabolic health, and highly individualized treatment. Through comprehensive blood testing, symptom assessment, careful dose adjustments, and ongoing patient monitoring, she helps men and women better understand how hormones, medications, and peptides may affect their energy, sleep, inflammation, fertility, body composition, and long-term health. Her approach challenges standardized protocols and social-media biohacking trends, emphasizing personalized medicine, responsible prescribing, and evaluating one intervention at a time.   Quick Coherence Technique — HeartMath https://help.heartmath.com/introduction/quick-coherence-technique/ The Levels of Ghrelin, Glucagon, Visfatin and GLP-1 Are Decreased in the Peritoneal Fluid of Women with Endometriosis — Aleksey M. Krasnyi et al. https://pubmed.ncbi.nlm.nih.gov/36142272/ Women's Health Initiative — National Heart, Lung, and Blood Institute, National Institutes of Health https://www.nhlbi.nih.gov/science/womens-health-initiative-whi Facial Beauty Age Support Serum for Estrogen Deficiency — Quicksilver Scientific https://www.quicksilverscientific.com/products/facial-beauty-serum Peptides: The Science, Uses & Safety — Dr. Andrew Huberman and Dr. Abud Bakri https://www.hubermanlab.com/episode/peptides-the-science-uses-and-safety-abud-bakri Vladimir Khavinson Publications — Professor Vladimir Khavinson https://khavinson.info/publications   Show Notes   00:00 Welcome to the Hart2Heart Podcast 00:57 GLP-1 Starting Doses 03:39 GLP-1 Anti Inflammation Aging 07:15 Motility Supplements Side Effects 09:02 Tirzepatide vs Semaglutide 11:46 Adrenal Fatigue Myth 13:23 Fatigue Bloodwork Checklist 16:16 TRT Hematocrit Sleep Apnea 19:01 Underrated Blood Tests 20:06 Womens HRT Basics 22:21 Testosterone for Women 25:19 Thyroid Treatment LDN NAD 29:31 Progesterone GABA Sleep 32:25 Progesterone for Men Debate 33:43 Testosterone Injection Frequency 36:05 TRT Dosing Frequency 36:45 Why TRT Stops Working 37:50 Creams vs Injections 39:08 Fertility and HCG 41:46 Peptides vs Pharma 44:17 HGH and Secretagogues 45:12 5-Amino-1-MQ Hype 48:15 Topical GHK-Cu Skincare 50:25 Injectable Copper Peptide Hair 52:26 BPC 157 and TB500 58:25 Thymosin Alpha 1 Immunity 01:01:13 Mitochondrial Peptides 01:03:20 Endo 205 and New Peptides 01:04:17 Kavinson and Epitalon 01:08:21 Wrap Up and Where to Find   The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being.   Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart

Why Women Need 7-20 Minutes to "Warm Up", And Why That's Normal | FT: NikkiCONNECT WITH CHARLENEOn Instagram @mscharlenebyars([https://www.instagram.com/mscharlenebyars]On YouTube @chosentraining(https://www.youtube.com/@lovestorieswithcharlenebyars))Work with me HERE([https://charlenebyars.com/](https://charlenebyars.com/))In this candid conversation, desire coach and sexuality educator Nikki joins the podcast to break down the anatomy and psychology of female arousal, information most women were never taught growing up.The episode covers the truth about clitoral anatomy (including why the "G-spot" debate is more nuanced than most people realize), the concept of "tenting" and why arousal needs time to build before penetration, and why the widely cited 7-20 minute warm-up window varies so much from person to person.TIMESTAMP:00:00 — Intro: Meet Nikki, Desire Coach & "Sextainer"02:15 — Nikki's Story: From Closed Off to Owning Her Pleasure04:30 — The 73-Year-Old Client Who Changed Everything07:00 — Why We Never Learned About Female Anatomy09:45 — Clitoris vs. G-Spot: The Real Statistics Explained13:00 — What "Tenting" Means & Why It Matters16:30 — How Arousal Physically Changes the Body19:00 — Why 7-20 Minutes to "Warm Up" Is Normal21:15 — Responsive vs. Spontaneous Desire23:00 — Homework: The Memory Exercise for Couples25:30 — How Pregnancy, Perimenopause & Menopause Change Desire28:00 — Medications That Affect Libido (Antidepressants, Semaglutide, Antihistamines)30:15 — Sexual Trauma & When to Seek Additional Support32:00 — Why Desire Changes as Women Age34:00 — Pillar #1: Agency — Reclaiming Choice37:00 — Pillar #2: Context — Setting the Right Environment40:30 — Pillar #3: Permission — Affirmations for Pleasure43:00 — Pillar #4: Sensation — Blood Flow, Hormones & Vasodilators47:30 — Testing Hormones the Right Way (Optimal vs. "Normal")50:00 — Pillar #5: Energy — Why Timing of Day Matters53:00 — The "2 PM vs 8 PM" Concept & App-Controlled Toys56:00 — Pillar #6: Mindset — Getting Out of Multitasking Mode59:00 — Why Desire Doesn't Have to Come First1:01:30 — Understanding Sexless Marriages & How Habits Form1:02:00 — The Importance of Non-Sexual Touch1:03:00 — Why Orgasms Matter for Mental & Physical Health1:04:00 — A Word on Men's Sexual Health1:06:00 — Lubricant 101: What to Look For & Why It Matters1:08:00 — Teaching Daughters About Their Bodies1:0900 — Where to Find Nikki + Free Resources1:10:00 — Closing Thoughts: "Happy Humping"The conversation also explores responsive versus spontaneous desire, how major life changes, postpartum, perimenopause, medication side effects, and past sexual trauma, can shift how the body experiences pleasure, and practical communication exercises couples can use to reconnect.Nikki introduces her "6 Pillars of Playfulness" framework (agency, context, permission, sensation, energy, and mindset) as a roadmap for women who feel like their desire has faded in long-term relationships, along with simple, low-pressure homework couples can try together.This is an educational, relationship-focused conversation aimed at demystifying female sexuality, encouraging open communication between partners, and helping women reconnect with pleasure without shame.

As current understandings of obesity (ie, a chronic disease requiring long-term management) are adopted across the world, screening and treatment can no longer follow a one-size-fits-all approach. Listen in as 3 global experts in obesity medicine highlight the emerging evidence from recent conferences that are changing real-world practice today. Learn how the latest findings apply to specific patient populations across the United States, Europe, and Asia as well as why healthcare professionals should individualize treatment based on patient preferences and relevant risk factors. Presenters: Stephano Del Prato, MD Professor Emeritus of Endocrinology University of Pisa Pisa, Italy Soo Lim, MD, PhD Professor of Medicine Department of Internal Medicine Seoul National University College of Medicine and Seoul National University Bundang Hospital Seoul, South Korea Donna H. Ryan, MD Professor Emerita Pennington Biomedical Research Center Louisiana State University New Orleans, Louisiana Link to full program:https://bit.ly/4pwFhEo Get access to all of our new podcasts by subscribing to the Decera Clinical Education Multispecialty Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In Part 1 we started discussing the study Two Years After Stopping GLP-1s, Most Patients Sustain at Least Some Weight Loss by Bartelt et al. which I identified as possibly the worst, and definitely among the top 3 worst, studies I've ever analyzed.In part 1 we talked about the platform (Epic Research), the researchers, and the basic methodology for reporting. Today we're going to get into the analysis. Remember that there are two sources, the first is the actual article, the second is what I am calling the supplementary materials that is a pdf that is linked (though not at all clearly) in the article.We'll compare the claims made in the article to the data shown in the supplementary materials. I think as we get into this it may be helpful (and maybe just a bit comforting) to remember that this was not published in a peer reviewed journal - it's Epic publishing Epic's research on Epic's website.We'll begin with the most basic claim: “we studied 188,722 patients who stopped using a GLP-1 medication after being on it for at least 90 days and who lost at least 5 pounds while on it.”You might be thinking “wait - in Part 1 you said the study population was 323,782, what happened to the other 135,060 people? Let's go on this journey together. We'll start by looking at their data. In the supplementary materials, Table 1: Characteristics of the Study Population looks like this:So they say in the article that they studied 188,722 patients but the very first line of the supplementary materials chart about the study population says that the total number of patients was 323,782. But it gets a bit weirder, if you add up all the participants in the different age categories you get 323,750, 32 short. If you add up the totals across the drug groups you do get 188,722, if you add up the participants in the weight loss category you get 323,782. If you add up the diabetic status you get 323,782. What is going on here? Maybe they originally looked at 323,782 records of which only 188,722 were not excluded for some reason, and maybe 32 of the participants did not have an age on their electronic health record? At least the number of people across the drug groups in the supplementary materials chart matches the number of people they claim to have studied but this is, in the absolute more charitable description, an extremely confusing way to present this data.In part 1 we discussed the fact that the inclusion criteria were not particularly stringent but the biggest issue, to me, is that the researchers appear to have just done calculations with whatever data they happened to have, but reported it and drew conclusions as if they had consistent data on all participants.For each of the three drug groups (semaglutide, liraglutide, tirzepatide), they present an interactive graph that shows “the proportion of patients by amount of weight regained or lost after stopping [liraglutide/semaglutide/tirzepatide].”Let's dig in.In the article we find Figure 1 - Proportion of Patients by Weight Change After Stopping Semaglutide we can see in the lower left “n=139,972 patients.”But if you look at the supplementary materials you find Table 2 Proportion of Patients by Weight Change After Stopping Semaglutide. This is the table from which they are drawing the data for Figure 1.The final column of the supplemental table is “patients” and the number in that column represents the number of the original 139,972 patients who had taken (and subsequently stopped taking) semaglutide for which the researchers had a weight at each month of their calculation. At month 1, the researchers had a weight for 68,754 of the patients and this number trends steadily downward until month 24 when they only had weights for 2,650 of the original 139,972 patients. At literally no point does Figure 1 in the original article give data for the n=139,972 patients the label claims.In the liraglutide group the graph in the article says n = 23,377. The supplementary tables show that in month 1 they had weights for 11,580. That steadily declined until month 24 they had weights for 1,268 of the population.In the tirzepatide group, the article says n= 25,373 patients. At month 1 they had weights for 12,909 patients which steadily declined until at at month 24 they only had a weight for 145 people (that is not a typo, they were doing the two year calculation upon which they drew their bold conclusions with only one hundred and forty five of the original 25k+ people represented!)This is such a bonkers way to do this that I actually emailed them, using the semaglutide table as an example, to make sure I was understanding this correctly. They assured me that I was:“Yes – there were 139,972 total patients on semaglutide who met the conditions in the study cohort. The patient count in Table 2 represents the number of patients that had a weight reading in a given month, so patients can be represented in multiple months.”So let's discuss the “key findings”At 24 months post-cessation, 56% of semaglutide, 52% of liraglutide, and 55% of tirzepatide patients kept the weight off or lost additional weight.Complete weight regain occurred in 23% of semaglutide, 21% of tirzepatide, and 27% of liraglutide users at 24 months.Weight trajectories stabilized after 12 months, with only small variations in the distribution of weight outcomes through year two.Remember that when they state these 24 month findings (or when in the title they say “Most Patients Sustain at Least Some Weight Loss,”) these statistics are drawn from information for only 1.9% of the semaglutide group, 5.4% of the liraglutide group, and 0.57% of the tirzepatide group. When they say kept the weight off or lost additional weight, subjects would qualify if they maintained 1% of the weight they lost. EDIT - I'm adding this paragraph for additional clarification based on a great comment below. If you look at their percentages, it can seem like a lot of people didn't regain weight. For example in the Semaglutide group, for example, at 1 month the “doubled their weight loss group” was 5.01% of 68,754 participants. That's that's about 892 people which is 0.64% of the original 139,972 people. At 24 months it was 25.89% of 2,650 people. That's about 686 people which is about 0.49% of the original 139,972 people. As I mentioned in part 1, we also don't know if this miniscule percentage of the total group even actually stopped taking the drugs, or if they started getting them from a different source that did not add them to their medical chart.What happened to the 98.1% of the semaglutide group, 94.6% of the liraglutide group, and the staggering 99.43% of the tirzepatide group for whom the researchers did NOT have a weight at 24 months? Is it more likely that people who were regaining weight did not come back to get weighed in? These researchers have absolutely no idea and they don't seem to care.(They said that weight trajectories stabilized at 12 months so even if we look at the data at 12 months they only had weights for 12.7% of the semaglutide group, 18.5% of the liraglutide group, and 8.1% of the tirzepatide group.)Under limitations they state “We allow a patient to be included in each month, using their highest weight in that month. Patients who have repeated weight measurements might be the extremes of weight change.”Gentle readers, I would say that this is the least of their limitations. The fact that they are stating these incredibly broad conclusions about weight regain (including in the title!) based on a tiny fraction of the data they've led us to believe is included, and that they AT NO POINT disclose any of that in the main paper is, to me, unforgivable. Horrifyingly, in researching this piece I found other studies that actually cited this one so I'll end this by saying that this study completely lacks the academic rigor or appropriate methodology necessary to be used to counter research showing high rates of weight regain after GLP-1 cessation. GLP-1s are being taken by a huge percentage of people and being prescribed (and in some cases pushed) by many prescribers, research like this has the potential to do incredible harm by generating blatant misinformation. We have to do a whole lot better than this.This month's online workshop is How to Be Your Own Medical Advocate. You'll learn strategies to advocate for yourself to help you get the evidence-based, compassionate, healthcare you deserve, and what your options are if you don't. There's a pay-what-you-can option to make sure money isn't a barrier and all registrants get a video in case you can't make it live. Details and registration are here! If you appreciate the work I do here, you can support my ability to do more becoming a free or paid subscriber!Liked the piece? Share the piece!More researchThe Research PostMore resourcesThe Resource Post*Note on language: I use “fat” as a neutral descriptor as used by the fat activist community, I use “ob*se” and “overw*ight” to acknowledge that these are terms that were created to medicalize and pathologize fat bodies, with roots in racism and specifically anti-Blackness. Please read Sabrina Strings' Fearing the Black Body – the Racial Origins of Fat Phobia and Da'Shaun Harrison's Belly of the Beast: The Politics of Anti-Fatness as Anti-Blackness for more on this. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to forge ahead, making significant strides in scientific advancements, regulatory approvals, and strategic business developments. These moves are reshaping the landscape of drug development and patient care. Starting with Merck & Co.'s recent FDA approval for Lipfendra, the world's first oral PCSK9 inhibitor, this marks a pivotal shift in managing hypercholesterolemia. Traditionally, PCSK9 inhibitors have been administered via injection, but Lipfendra offers a more convenient oral alternative. This could significantly improve patient adherence and outcomes by easing the administration process for those managing cholesterol levels. The drug's approval highlights a crucial advancement in cardiovascular treatment, with expectations of reaching peak annual sales of $5 billion, underscoring its market potential. In another significant development, Eli Lilly has entered the burgeoning field of psychedelic therapeutics with its acquisition of Ataibeckley for up to $3.8 billion. This move reflects a growing trend toward exploring novel therapeutic avenues for psychiatric disorders. Psychedelic compounds promise new hope for patients with depression and other mental health conditions where conventional therapies have shown limited efficacy. Eli Lilly's investment signals confidence in the transformative potential of psychedelics, which could revolutionize treatment paradigms for conditions like depression and PTSD. Turning to obesity treatment, Novo Nordisk's Wegovy pill has received European Commission approval for obesity and overweight adults. As a small molecule GLP-1 receptor agonist, semaglutide enhances satiety and reduces caloric intake. This development underscores the increasing focus on metabolic disorders and highlights the competitive landscape as companies race to dominate the weight management sector with innovative oral formulations. In oncology news, Merck & Co.'s Keytruda has achieved a milestone in becoming the first PD-1 inhibitor to demonstrate phase 3 benefits as a single agent in frontline mismatch repair-deficient endometrial cancer. This success not only reinforces Keytruda's role in oncology but also emphasizes the importance of precision medicine approaches targeting specific genetic mutations in cancer therapy. The industry is also seeing substantial financial maneuvers aimed at bolstering research capabilities and market reach. Johnson & Johnson has raised its 2026 financial guidance following Tremfya's impressive $2 billion revenue milestone with its IL-23 inhibitor for autoimmune diseases. Additionally, their strategic supply chain restructuring reflects efforts to enhance operational efficiency amid a broader U.S. manufacturing push. On the regulatory front, Johnson & Johnson received UK MHRA approval for Akeega in BRCA1/2-mutated metastatic prostate cancer, highlighting ongoing focus on precision medicine and targeted therapies in oncology. Meanwhile, Medtronic's recall of Harmony Catheter Delivery Systems due to safety concerns serves as a reminder of ongoing vigilance in medical device safety regulations. In clinical trial advancements, InnoCare Pharma's TYK2 inhibitor demonstrated efficacy in a Phase 2 trial for nonsegmental vitiligo, achieving its primary endpoint and paving the way for Phase 3 studies. This highlights TYK2 inhibition as a promising strategy for autoimmune diseases like vitiligo. Moreover, we witness movements towards public offerings with companies like Vogenx and Braveheart Bio aiming for IPOs to fund their respective drug development projects. These efforts underscore the continuous drive for capital to propel innovative therapies through clinical trials and towards commercialization. Finally, turning to regulatory updates, Sanofi has entered new chapters in mRNA patent litigation against Pfizer and Moderna, reflecting ongoing tensions over intellectual property rights within the high-stakes realm of COVID-19 vaccines and mRNA technology. The outcomes here could have far-reaching implications for mRNA-based therapeutics and vaccine development. As we look at these developments collectively, they illustrate a vibrant period for pharmaceutical and biotech companies innovating new treatments while navigating complex regulatory terrains. The implications for patient care are profound, with potential improvements in therapeutic options driven by new scientific breakthroughs and strategic industry shifts. These dynamics promise to reshape the future landscape of global healthcare delivery and pharmaceutical innovation as these trends continue to unfold.Support the show

A Note from James:I'm doing a big experiment in my life.I recently started taking a GLP-1—tirzepatide, one of the so-called weight-loss drugs. But I didn't start taking it specifically for weight loss. I had some blood work done for the first time in a long time, and there was a small indication that I might be pre-diabetic. My doctor suggested trying tirzepatide, and I wanted to understand what I was getting into.The first person I wanted to talk to was Charles Duhigg, author of The Power of Habit and Supercommunicators. Charles has been taking a GLP-1 for about two years, and he says it has changed his life. He has lost around 45 pounds, but what interested me most was not just the weight loss. It was the habit change.Charles explains that GLP-1s can quiet what people now call “food noise”—the constant background pull toward eating even when you are not actually hungry. When that noise quiets down, something interesting happens: you get a window where your old habits become more malleable.That is the key idea of this conversation. The drug may help you eat less, but the bigger opportunity is that it gives you a chance to build new routines around food, exercise, alcohol, sleep, and identity. And if you build those habits while the window is open, those habits may continue even after you stop taking the medication.We talk about food noise, cravings, the habit loop, keystone habits, stated versus revealed preferences, placebo effects, alcohol, sleep, exercise, blood sugar, identity, and whether GLP-1s are a lifelong drug or a tool for changing who you become.Episode Description:James is at the beginning of a GLP-1 experiment. Charles Duhigg is two years in.In this conversation, Charles explains what he has learned from taking tirzepatide and from studying GLP-1s through the lens of habit formation. He describes the first phase of public understanding around these medications as weight loss. Phase two, he argues, is about behavior change.The central concept is “food noise.” Charles describes it as the background craving that turns a basket of fries into an almost automatic behavior. You may not even notice the noise until it goes away. Once it quiets, the cue that normally triggers the habit loop weakens. That creates a temporary window where new habits can be built.James and Charles use the GLP-1 experience to revisit the basic habit loop: cue, routine, reward. They talk about why habits feel automatic, why willpower is often the wrong tool, and why successful behavior change depends on identifying the cue and replacing the routine while still satisfying the underlying reward.Charles also introduces the idea of GLP-1s as a catalyst for keystone habits. Eating less can make exercise easier. Drinking less can improve sleep. Better sleep can improve focus. Focus can improve work. One changed habit can set off a chain reaction.The conversation then becomes more philosophical: Who are we if one part of the brain says “I want to be healthy,” while another part of the brain keeps revealing different preferences through action? Charles explains the difference between stated preferences and revealed preferences, and how repeated behavior can shift identity.This is not a conversation about taking GLP-1s casually. It is a conversation about using a medical intervention deliberately, under appropriate medical guidance, as a chance to change the patterns that shape daily life.Editorial Note:This episode discusses prescription medications, including tirzepatide and semaglutide, as well as personal experiences with GLP-1 drugs. It should not be treated as medical advice.GLP-1 medications can have side effects and risks, including gastrointestinal symptoms, dosing concerns, and contraindications for some patients. They should be used only under the supervision of a qualified medical professional. Any decision to start, stop, adjust, or combine medications should be made with a clinician.James and Charles also discuss personal experience, habit change, appetite, alcohol cravings, and identity. Individual responses to these medications vary.What You'll Learn:Why Charles believes GLP-1s are entering “phase two”: not just weight loss, but habit change.What “food noise” feels like—and why people often do not notice it until it disappears.How GLP-1s may create a temporary “habit window” where old routines become easier to change.Why the habit loop—cue, routine, reward—matters when trying to change eating behavior.Why people often regain weight after stopping GLP-1s if they have not built new habits.How keystone habits can create a chain reaction across food, exercise, alcohol, sleep, and focus.Why micro habits may work better than a full lifestyle overhaul.How stated preferences and revealed preferences shape identity.Why eating less can make exercise easier, and why exercise can reinforce healthier choices.Why tracking behavior may be essential while taking a GLP-1.How placebo, alter egos, and rituals may influence identity and performance.Why the goal is not just losing weight, but becoming the kind of person whose habits support health.Timestamped Chapters:[03:36] James Begins His GLP-1 ExperimentJames explains his early experience, including confusion between medication side effects and a bout of COVID.[04:16] Charles's Two-Year ExperienceCharles describes taking tirzepatide, losing roughly 45 pounds, and why the biggest changes came months into the process.[05:38] Phase One vs. Phase Two of GLP-1sPhase one was about appetite and weight loss. Phase two, Charles argues, is about habits that can last.[06:42] The Habit WindowHow GLP-1s can quiet food noise and create a period where eating habits become more malleable.[07:21] COVID, Side Effects, and Early SignalsJames explains why his first few weeks were hard to interpret and why he is still figuring out what the medication is doing.[09:00] What Food Noise Actually Feels LikeCharles uses the example of a basket of fries to explain cravings, cues, and automatic eating.[09:55] The Habit Loop: Cue, Routine, RewardCharles revisits the framework from The Power of Habit and applies it directly to food cravings.[10:42] How GLP-1s Interrupt the CueThe fries are still there, but the craving does not activate in the same way.[11:40] What GLP-1s Do in the Body and BrainCharles explains what researchers know about gastric emptying, glucagon-like peptides, and what remains uncertain about the brain.[12:43] What Happens When You StopWhy the medication alone may not be enough if old habits return after discontinuation.[13:36] Pleasure, Food, Alcohol, and AnhedoniaCharles discusses reduced pleasure from food and alcohol, while separating clinical findings from broader claims about losing joy in life.[15:54] Why Charles Stayed With ItEarly changes were not dramatic weight loss, but a growing feeling that eating became more of a choice.[16:40] Eating as a Keystone HabitHow changing food behavior can trigger changes in exercise, alcohol, sleep, focus, and work.[19:31] Why Structure MattersCharles explains why tracking and guided habit systems can help people see patterns they might miss on their own.[20:32] What Changes Physically Over TimeSlower stomach emptying, feeling full longer, more stable blood sugar, and gradual changes in appetite.[21:43] Stated Preferences vs. Revealed PreferencesWhy one part of the brain says “I want to change,” while another part watches what you actually do.[23:22] Identity Change and Habit FormationHow repeated behavior can teach the brain, “I am the kind of person who eats this way” or “I am the kind of person who exercises.”[24:16] Placebo, Belief, and Becoming the Person You Want to BeJames and Charles explore whether placebo effects may work partly by changing identity.[28:07] Alter Egos, Athletes, and RitualsThe conversation turns to Kobe Bryant, Michael Phelps, and how pre-performance routines can cue a desired identity.[29:15] Start With Micro HabitsCharles explains why small behavior changes can compound more effectively than trying to overhaul an entire life at once.[30:40] Charles's First Micro HabitsDrinking less, eating fewer fries, stopping when full, and choosing healthier meals without relying on willpower.[31:24] Feeling Full for the First TimeCharles describes the surprising experience of leaving food unfinished because his body had had enough.[33:03] Why the Stomach ShrinksThe medication does not shrink the stomach directly; eating less over time changes how much food the body expects.[33:21] Why Slower Stomach Emptying HelpsJames asks why a weight-loss drug would slow digestion instead of speeding metabolism.[35:00] The Cumulative EffectWhy the most visible changes often appear after several months, once habits, body size, and identity begin reinforcing each other.[37:03] Is a GLP-1 a Lifelong Drug?Charles explains what research and personal experience suggest about stopping, restarting, and maintaining results.[38:56] James's Health MotivationJames explains that his motivation is not primarily weight loss, but a desire to respond to possible pre-diabetic markers.[39:36] Why Attitude Is Not EnoughCharles argues that wanting to be healthy helps, but habit change still requires structure.[40:02] What Changed at HomeCharles explains how his family's food did not need to change, even though his own choices and portions did.[41:02] Weight, Body Composition, and Pre-DiabetesWhy blood sugar, insulin resistance, fat, and muscle matter more than the scale alone.[42:38] Semaglutide, Tirzepatide, and What Comes NextJames and Charles compare different GLP-1 medications and discuss how newer drugs may work through multiple receptors.[44:27] Will Charles Stop Taking It?Charles explains why he may eventually discontinue the medication, but values having more choice over weight and behavior.[45:24] Blood Work, Snoring, and Health MarkersCharles describes improvements in lab results, cholesterol, snoring, and overall health.[46:31] Who Are We, Really?James and Charles talk about identity, brain chemistry, sugar, alcohol, cravings, and the substances that shape behavior.[48:32] Choosing the Person You Want to BecomeCharles explains how better self-awareness can help people change habits deliberately rather than being pulled by cravings.[49:00] Tracking the ExperimentCharles advises James to track food, feelings, and behavior so he can notice changes that might otherwise be invisible.Additional Resources:Charles Duhigg Official WebsiteThe Power of Habit by Charles DuhiggSupercommunicators by Charles DuhiggNoom's GLP-1 Companion / Habit Formation AnnouncementFDA: Zepbound Approval for Chronic Weight ManagementFDA: Concerns With Unapproved GLP-1 Drugs Used for Weight LossBMJ: Weight Regain After Stopping Weight-Loss MedicationTodd Herman — The Alter Ego EffectSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

REPLAY! Bariatric surgery is the most effective tool for lasting weight loss, and her experience performing thousands of procedures has given Dr. Betsy Dovec a clear understanding of what can help patients succeed.In this episode of Wellness Junkies, host Amy Sherman sits down with Dr. Dovec, a top female bariatric surgeon and founder of BodyByBariatrics, to break down the decision between bariatric surgery vs GLP-1 medications from the perspective of someone who treats patients with both options every day. Dr. Dovec explains what gastric bypass surgery involves, why some patients go home the same day, and who may be an ideal candidate.The conversation then turns to GLP-1 weight loss medications. Amy and Dr. Dovec compare Ozempic and Zepbound, the often-overlooked side effects, and explain why weight regain is common after patients stop taking these medications. Dr. Dovec also shares why some post-surgery patients respond well to GLP-1 medications and how the combination may help support their long-term results.For women in midlife, this episode examines how GLP-1 medications may fit into treatment for weight gain during perimenopause and menopause. Dr. Dovec explains why the habits you once relied on may become less effective as your hormones shift. She also discusses the health risks associated with visceral fat and the potential role of GLP-1 treatment in reducing the internal fat linked to heart attacks, strokes, and fatty liver disease.If you have tried every diet and still feel stuck, this conversation about bariatric surgery and GLP-1 medications offers a clearer framework for understanding your options.Episode Breakdown:00:00 Meet Bariatric Surgeon Dr. Betsy Dovec01:28 What Gastric Bypass Surgery Actually Involves04:55 Who Qualifies as a Bariatric Surgery Candidate06:30 Bariatric Surgery vs GLP-1 for Long-Term Success09:37 Why GLP-1 Medications Are a Hot Topic10:57 Semaglutide and Tirzepatide Dosing Explained13:34 Same Drug Different Label for Diabetes and Weight Loss15:54 Oral GLP-1 Pills and What Comes Next17:25 Brand-Name vs. Compounded GLP-1 Medications21:13 GLP-1 Benefits During Perimenopause and Menopause23:13 Breaking the Stigma Around GLP-1 Use27:26 Visceral Fat Differences in Men and Women30:55 Sugar, Fatty Liver, and Visceral Fat Risks32:56 How Surgery and GLP-1 Both Reduce Visceral Fat36:40 Inside the OR Surgery Time and Recovery38:38 Dr. Dovec's Beauty and Self-Care Routine48:07 Where to Find Dr. Betsy DovecConnect with Dr. Betsy Dovec:Follow Dr. Dovec on InstagramVisit the BodyByBariatrics WebsiteFollow BodyByBariatrics on TikTok⁠⁠⁠⁠For More on this Episode: Read the full show notes ⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠

Join primary care professors Mark Ebell, Kate Rowland, Gary Ferenchick and Henry Barry as they discuss 4 new studies: semaglutide for alcohol use disorder, a vibrating cool pack to prevent post vaccination syncope, PCR for 23 respiratory pathogens in primary care to reduce antibiotic use, and fluvoxamine for Long-COVID Fatigue.LinksSemaglutide for AUD: https://pubmed.ncbi.nlm.nih.gov/42070571/Vibrating cool pack for vaccine syncope: https://pubmed.ncbi.nlm.nih.gov/41692229/ Point of care PCR for acute RTI: https://pubmed.ncbi.nlm.nih.gov/42149561/Likelihood that pathogen is commensal vs pathogenic: https://pubmed.ncbi.nlm.nih.gov/39864052/ Fluvoxamine and long COVID: Ann Intern Med. 2026;179(5):621-628  https://pubmed.ncbi.nlm.nih.gov/41911553/

(00:00:00) 224: DOCs Itchy&Bitchy Answer YOUR Questions - Global Edition! (00:00:11) Welcome to Itchy and Bitchy (00:00:42) Doc Itchy Medical Pets Supplements (00:02:32) Hormone Replacement and GLP-1: Navigating Medical Decisions (00:08:06) Brain Fog and Alzheimer's: When to Worry (00:11:11) Menopause in Dogs: A Misunderstanding (00:16:48) The Truth About Alcohol Consumption (00:22:10) GLP-1 and Addiction: A Complex Discussion (00:27:41) Probiotics: The Unknown Frontier (00:32:05) Closing Thoughts on Supplements and Health Ask Docs Itchy&Bitchy:Your Questions on Weight, Hormones, and the GLP-1 additction ...You're writing in from everywhere, and your questions don't hold back, so neither will we. Why is your dog carrying extra weight even though nothing about mealtime has changed? On the human side: does Ozempic actually rewire your brain's reward system, not just your appetite? Emerging research says GLP-1 drugs quiet the same dopamine pathway that drives cravings for food, alcohol, and drugs which raises a wild question we're tackling this season: could a diabetes drug end up treating addiction? We're also digging into whether "Ozempic personality changes" are real, why weight-loss drugs hit women differently at midlife, and what nobody's telling you about pet supplements.Got a question? Send it — nothing's off limits.Visit itchyandbitchy.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/itchy-bitchy-podcast--4303608/support.Itchy & Bitchy: Have you felt dismissed, misdiagnosed, or gaslit by a broken medical system.  From gut health, hormones, autoimmune disease, chronic pain, holistic health, and alternative medicine ... medical gaslighting, patient advocacy , or misdiagnosis we'll call that too.  For chronic illness warriors, self-advocacy seekers: WE OFFER  No BS 

In this episode, I'm joined by board-certified OBGYN and integrative medicine physician Dr. Shawn Tassone to break down one of the fastest-growing topics in health today: peptides. We discuss what peptides are, how they work in the body, and why they've become so popular for everything from weight loss and longevity to muscle recovery and inflammation. We also take a closer look at some of the most talked-about peptides, including semaglutide, tirzepatide, BPC-157, MOTS-c, tesamorelin, and more, discussing the current research, potential benefits, safety concerns, and which ones may actually be worth considering. If you've ever wondered whether peptides are the future of medicine or simply the latest health trend, this episode is for you!

Is Ozempic secretly slowing down your thyroid? Millions are using GLP-1 medications like Ozempic for weight loss and blood sugar control, but very few people are being warned about what they could be doing to their thyroid health.If you're experiencing fatigue, hair loss, brain fog, cold hands and feet, constipation, or stubborn weight loss plateaus after starting Ozempic, your thyroid may be sending you warning signs that are often overlooked.In this eye-opening episode of Accelerated Health with Sara Banta, I uncover the surprising connection between Ozempic, GLP-1 medications, and thyroid function, why standard thyroid testing may miss the problem, and the essential nutrients your thyroid needs to function properly.If you're taking Ozempic, Wegovy, Mounjaro, or another GLP-1 medication, this is information you don't want to miss.Supplements Featured In This Episode:• Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care• Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement Not sure what food to eat and avoid? This guide is for you.⬇️

In this episode of Girl Talk with Tay, I sit down with Bracha Banayan, family nurse practitioner, entrepreneur, and founder of IVDrips and Hello Dose, for one of our most fascinating conversations yet. We dive into the science behind GLP-1 medications, why they're about so much more than weight loss, and how they're changing the conversation around longevity, metabolic health, and healthy aging.Bracha explains how GLP-1s work in the body, why weight gain is often rooted in biology rather than willpower, and how factors like glucose, insulin, inflammation, and hormones all play a role in long-term health. We also discuss who may benefit from GLP-1 medications, including women navigating perimenopause and menopause, adults focused on cardiovascular health, and those looking to improve metabolic wellness.We also get into fertility, blood sugar, continuous glucose monitors, and the surprising ways GLP-1s may help reduce cravings by working on the brain's reward system. Beyond medications, Bracha shares the foundational habits she believes everyone should prioritize first from walking after meals and getting morning sunlight to improving sleep and building sustainable wellness routines.Whether you're curious about GLP-1s, trying to better understand metabolic health, or looking for practical ways to optimize your health for the long run, this episode is packed with insights and actionable takeaways.xo, Tay⸻Follow Bracha Banayan!

Before EP Description: Learn about the Healing Power of Prolonged Fasting: HEREWhat if losing weight on a GLP-1 drug and losing weight through fasting produce the same number on the scale, but nearly opposite effects inside your cells?Host Dr. Katie Deming believes some of the most popular weight loss drugs on the market may be quietly blocking one of your body's most essential repair processes. Not because they're failing to work, but because they work in a way that keeps your body in a state it was never meant to stay in.She takes an honest, no-shame look at GLP-1 drugs like Ozempic and Wegovy and compares what's actually happening inside your body when you lose weight on them versus when you fast. The scale might show the same number. The story underneath is very different. Dr. Katie explains a repair switch your body can only flip when your stomach is genuinely empty, and why keeping it perpetually fed may keep that switch turned off for good. She connects the dots between mitochondrial health, cellular cleanup, visceral fat, muscle preservation, and metabolic flexibility in a way that's clear, honest, and direct.She's not here to shame anyone taking these medications. She gets why people reach for something that works. But she shares what happened when several of her patients who were certain they'd go right back on the drug after fasting decided they didn't want to, and why.Chapters:00:04:23 - The Food System Is Broken00:06:13 - Your Body Needs Empty Space00:08:24 - GLP-1s May Block Repair Mode00:10:41 - Weight Loss Is Not Healing00:12:26 - What Cancer Cells Feed On00:13:30 - Fasting Changes the Terrain00:17:00 - Cleaning Out Damaged Mitochondria00:18:00 - The Most Dangerous Fat00:20:35 - The Hidden Muscle Loss Problem00:22:20 - Clients Who Were on GLP-1s Before Fasting00:26:06 - Who Should Never Water Fast If you've ever wondered whether weight loss and true healing are actually the same thing, or why one of her patients gained lean mass six weeks after a 14-day water fast, this episode will change how you think about what your body actually needs.Press play and learn why the repair process your body is waiting to run may only start when you finally stop feeding it.Join Dr. Katie's 3-Day Guided Fast, for expert support, daily live calls, and a community to fast alongside: Sign-Up Follow Dr. Katie Deming on InstagramWatch on YoutubeDISCLAIMER: The Born to Heal Podcast  is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.A thought-provoking podcast explores cancer through the lens of holistic medicine and functional medicine, discussing causes of cancer, metabolic health, and unconventional approaches like water fasting, fasting and autophagy, and detox, while weighing fasting benefits against chemo side effects and radiation side effects, sharing stories of a cancer survivor navigating chemotherapy, natural medicine, holistic healing, and even spiritual healing on the path toward cancer remission and holistic health. 

There is a fundamental link between diabetes and kidney care. But while there are many medications available to improve CKD outcomes in people with type 2 diabetes, the same options are not available for people with type 1. In this special episode, Dr. Neil Skolnik speaks with Janet McGill, MD, MA, FACE, FACP about the underdiscussed prevalence of CKD in type 1 and the importance of continued development in this area. This special episode is sponsored with support from Bayer. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Janet B. McGill, MD, MA, FACE, FACP, Professor of Medicine at the University of Washington's John T. Milliken Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research Selected References: Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260 Finerenone in Type 1 Diabetes and Chronic Kidney Disease. N Engl J Med 2026;394:947-957 Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121

Broadcast from KSQD, Santa Cruz on 7-02-2026: Dr. Dawn devotes the first half of the show to a nuanced defense of GLP-1 receptor agonists, arguing the polarized debate treats obesity as a moral failure rather than a physiological one. She recounts the "Marilyn Monroe dress" moment that transformed semaglutide from diabetes drug into elite cosmetic tool, and pushes back on the puritanical framing that behavior change must be earned rather than pharmacologically enabled—noting we don't apply this logic to antihypertensives or statins. Dr. Dawn catalogs visceral fat as a genuine endocrine organ producing over 17 hormones, most of which drive self-perpetuating growth: leptin (this satiety hormone at high levels disables it's own brain receptor), IL-6, TNF-alpha (blocks insulin), resistin (increases insulin resistance and inflammation), PAI-2 (blocks clot breakdown, raising cardiovascular risk), retinol-binding protein 4 (impairs muscle glucose uptake), chemerin (recruits macrophages and directs fat to the belly), and visfatin. Only adiponectin declines with rising visceral fat. It improves insulin sensitivity, suppresses hepatic gluconeogenesis, and blocks IL-6 . Dr. Dawn describes GLP-1's neurobiological action: receptors in the hypothalamus, brainstem, hippocampus, and mesolimbic reward system, with the drugs quieting the brain's salience network so food loses its intrusive pull. Taste buds shift, sweet and salty become muted, and reward circuits stop firing on cheat foods—creating a window during which behavioral change becomes possible. Dr. Dawn frames group support through self-determination theory (autonomy, competence, relatedness), arguing GLP-1s create the cognitive bandwidth for behavioral programs to succeed. A Tufts study of patients discontinuing after 10% weight loss found those enrolled in behavioral support programs regained about three times less weight than usual-care controls, outperforming even medically-tailored meal plans. Group engagement doubled the time patients stayed on the medication. A November 2025 Nature study piggybacked on deep brain stimulation research at Penn. Electrodes implanted in the nucleus accumbens of post-bariatric patients recorded low-frequency brain activity surges during food-noise episodes on drug free patients. A third participant who started tirzepatide showed complete silencing of that signature—the first direct electrical confirmation that GLP-1s suppresses compulsive food thoughts in the reward center. RNA sequencing of adipose tissue from 25 obese patients before and after bariatric surgery, compared to 24 lean controls, revealed persistent epigenetic changes even after weight loss. Lipid-associated inflammatory macrophages drop but retain some of their pro-inflammatory epigenetics, explaining the well-known slippery slope back to obesity—and why Dr. Dawn suggests GLP-1s may work best as intermittent tools when behavioral maintenance starts slipping. An emailer asks about long-term smoking versus vaping data. Dr. Dawn notes there is no long-term data yet, but short-term evidence shows e-cigarettes contain nicotine, propylene glycol, reactive oxygen species, and nitrosamines, producing spirometry readings similar to mild COPD in otherwise-healthy vapers. Vaping over a year raises stroke relative risk by 1.62 and nearly doubles MI risk, and combining smoking and vaping produces a multiplicative rather than additive harm. Data on cancer will take decades to emerge. Researchers built a functioning underwater breathing apparatus for cockroaches with electrodes attached to brain and sensory organs allowing remote-controlled direction while preserving natural obstacle-navigation autonomy. The 10mm × 10mm sponge-based oxygen tank uses magnesium dioxide catalyzing hydrogen peroxide breakdown, delivering oxygen through silicone tubes to the roach's spiracles for up to three hours underwater. Deployemenet will improve search-and-rescue in flooded and collapsed structures where dogs cannot reach. A Science Advances paper from Yong Lin Kong's lab at Rice University describes 3D-printing electronic circuits directly onto living tissue. Researchers achieved microwave-focused annealing at sub-200-micrometer resolution. By selectively heating only conductive ink particles (copper, silver, gold) without damaging surrounding tissue, the technique enables printing circuits onto 3D-printed heart valves, tracheas, and ear scaffolds, potentially creating combined graft-and-sensor implants, ingestible diagnostic devices, and perhaps even decorative electronic tattoos. A single-shot reformulation of zanamivir (originally the inhaled flu drug Relenza) provided 76.1% flu protection in a 5,000-participant trial—far exceeding the roughly 40-45% offered by annual flu vaccines. Because zanamivir targets neuraminidase in a way that inactivates it if the virus tries to mutate around the drug, trapping newly-made viral copies inside their host cells, this approach works across all flu strains and could bypass the annual guessing game of trivalent vaccine formulation.

GLP-1 receptor agonists have become some of the most talked-about medications in recent years. You may have heard names such as liraglutide, semaglutide (Ozempic and Wegovy), and tirzepatide (Mounjaro). These treatments have attracted attention because they can significantly reduce appetite and support weight loss while also helping to manage blood glucose levels. The breakthrough came when researchers developed long-acting versions of hormones naturally released by the body after eating, including GLP-1 and, in some cases, GIP. These hormones help regulate hunger and promote feelings of fullness. While the body's natural response lasts only a short time, modern medications extend these effects for up to a week with a single injection. Since results from major clinical trials emerged in the early 2020s, GLP-1 therapies have transformed obesity treatment, delivering weight-loss outcomes that surpass those achieved by previous medications and offering new hope for people struggling with weight management. - Laureate Professor Clare Collins, internationally distinguished leader in nutrition and dietetics, University of NewcastleSee omnystudio.com/listener for privacy information.

On today's Good Day Health Show - ON DEMAND…Dr. Jack Stockwell, a NUCCA Chiropractor and GAPS Practitioner in SLC, UT (866.867.5070 | ForbiddenDoctor.com | JackStockwell.com), shares a holistic perspective on health news today. Dr. Jack offers an insightful discussion challenging common beliefs about cholesterol, aging, and the role nutrition plays in maintaining long-term health. Dr. Jack examines widespread misconceptions surrounding cholesterol, explaining why it is an essential component of the body and discussing research suggesting that excessively low cholesterol levels—particularly in older adults—may be associated with certain health risks. The conversation explores the relationship between cholesterol and healthy aging, while encouraging listeners to better understand cholesterol's many functions beyond cardiovascular health.The episode also takes a closer look at the growing use of GLP-1 weight-loss medications, including Ozempic, and discusses concerns about their potential impact on connective tissue, muscle mass, and overall body composition during significant weight loss. Dr. Jack emphasizes the importance of supporting connective tissue through proper nutrition, adequate protein intake, essential nutrients, and healthy lifestyle habits that promote strength, mobility, and resilience as we age.Throughout the discussion, Doug and Dr. Jack examine how nutrition, inflammation, and lifestyle choices influence the aging process and overall wellness. They also explore the role the medical industry has played in shaping public perceptions of cholesterol and heart health, encouraging listeners to consider a broader perspective when evaluating their own health decisions. The episode concludes with practical strategies for supporting connective tissue health naturally, providing listeners with actionable insights for maintaining strength, mobility, and overall well-being throughout every stage of life.For more on Good Day Health…Website: GoodDayHealthShow.comSocial Media: @GoodDayNetworks

Thinking about starting Ozempic for weight loss or type 2 diabetes? Already taking it and wondering if you should stop? Before making any decision, listen to this important information.In this episode of Accelerated Health with Sara Banta, I break down the science behind Ozempic, how it works, who may benefit from it, the potential risks of stopping too soon, and what you should know before beginning treatment. You'll also learn why addressing your overall metabolic health is essential for long-term success—not just relying on medication alone.Whether your goal is healthy weight loss, improving blood sugar, or understanding the pros and cons of GLP-1 medications, this episode provides practical insights to help you make informed decisions with your healthcare provider.If you're considering Ozempic, Wegovy, or other GLP-1 medications, this is an episode you won't want to miss.Supplements Featured In This Episode:• Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care • Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement • Accelerated Fast®  https://www.acceleratedhealthproducts.com/products/accelerated-fast-supplement Not sure what food to eat and avoid? This guide is for you.⬇️

In this podcast, Jennifer Green, MD, and Jay H. Shubrook, DO, FAAFP, FACOFP, share strategies for integrating incretin-based therapies in type 2 diabetes (T2D) management in the primary care setting, including: Importance of moving beyond a glucose-centric approach to T2D care  Current evidence for incretin-based therapies in T2D Rationale for integrating these therapies into the primary care setting Shared decision-making strategies to discuss optimal T2D treatment options with patients Timing for endocrinology referral Presenters: Jennifer Green, MD Professor of Medicine Division of Endocrinology Duke Clinical Research Institute Duke University School of Medicine Durham, North Carolina Jay H. Shubrook, DO, FAAFP, FACOFP Professor, Diabetologist Department of Clinical Sciences and Community Medicine Touro University California, College of Osteopathic Medicine Vallejo, California Full program link: https://bit.ly/4uSKCqv Get access to all of our new podcasts by subscribing to the Decera Clinical Education Multispecialty Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Adding a cash-pay service to an insurance-based practice may seem like a simple way to grow revenue, but it can introduce significant compliance risk. This fan-favorite episode explores how a cardiology practice's weight loss program created patient confusion, operational headaches, and unexpected legal exposure. Tune in for compliance considerations to keep in mind when blending payment models.Chapters[00:00] Intro[1:12]  Banter  [06:08]  Story  [16:02]  Access+  [16:38]  Legal Takeaways  [29:05]  OutroWatch full episodes of our podcast on our YouTube channel: https://www.youtube.com/@byrdadattoStay connected for the latest business and health care legal updates:WebsiteFacebookInstagramLinkedIn

The World Cup is here, and while we watch some of the world's greatest athletes competing on a global stage, it's fascinating to consider what effect this intense activity may have on the human body. With that in mind, we're re-releasing our conversation with Stanford biochemist Jonathan Long on the future of exercise. Jonathan studies the chemistry of what happens inside your body when you move, and his findings are pointing toward some genuinely surprising possibilities — including treatments for obesity, diabetes, and even, someday, an exercise pill. If the athleticism on the pitch has you feeling inspired, this one is well worth another listen. Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu. Episode Reference Links: Stanford Profile: Jonathan Long Connect With Us: Episode Transcripts >>> The Future of Everything Website Connect with Russ >>> Threads / Bluesky / Mastodon Connect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / Facebook Chapters: (00:00:00) Introduction Russ Altman introduces guest Jonathan Long, a professor of pathology from Stanford University. (00:02:02) Effective Weight Loss Drugs The history and development of GLP-1 receptor agonists. (00:04:04) Understanding Metabolism and Exercise Why Long's lab starts with molecules to understand metabolism and physical activity. (00:05:10) Animal Models in Exercise Studies The use of animal models in exercise studies and the discovery of Lac-Phe. (00:06:47) Psychological Preparation for Exercise The psychological aspects of exercise and the involvement of endocannabinoids in exercise motivation. (00:09:00) Lac-Phe's Role and Mechanism The role of Lac-Phe and its production in the gut. (00:12:08) Differences in Exercise Response Differences in exercise response between trained athletes and untrained individuals. (00:12:57) Diabetes and Metabolic Diseases The relationship between diabetes, exercise, and metabolic diseases. (00:15:01) Lac-Phe as a Potential Therapeutic The potential of Lac-Phe as a weight loss drug, and parallels to GLP-1 drug development. (00:16:21) Importance of How Weight is Lost Whether the method of weight loss matters, and the importance of preserving lean muscle mass. (00:18:37) Exercise as Medicine The concept of exercise as medicine, and defining physical activity at the same resolution as modern medicines. (00:22:11) Metformin and Exercise Pathways The unexpected connection between metformin and the Lac-Phe pathway. (00:24:01) Prospects of an Exercise Pill The future of an exercise pill, and the challenges associated with its development. (00:27:05) Conclusion Final thoughts on the future of exercise. Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

GLP-1 drugs were first approved to treat diabetes and then caused a frenzy when it was discovered they were great for weight loss. But now scientists are discovering the drugs that have brand names including Ozempic and Mounjaro might offer so much more, from reducing the risk of heart attack to treating kidney disease. Today, Doctor Paul Joyce, a pharmaceutical scientist at Adelaide University on how Ozempic is shaking things up, again. Featured:  Doctor Paul Joyce, a pharmaceutical scientist at Adelaide University 

Semaglutide. Tirzepatide. Retatrutide. The peptide conversation has taken over every gym, group chat, and social media feed. But the part about muscle loss, osteopenia, and what the gray market is actually selling you? That part is getting buried. Chalene Johnson sits down with Adam Schafer, co-host of Mind Pump, one of the top fitness podcasts in the world with nearly half a billion downloads. Adam spent three and a half years running real test groups on GLP-1s including Ozempic and Wegovy. What he found changed his perspective entirely and he is not holding back. This conversation covers what is actually driving muscle and bone density loss in women over 40 and 50, why the scale and the mirror are lying about body composition, and what most women are getting wrong about building real strength in midlife. Plus the truth about the gray market and what those peptides may actually contain. This is the conversation the fitness industry is not having and it is one every woman over 40 needs to hear.

In part two of the GLP-1 series, Melissa gets practical. What does it actually feel like to be on this medication? What does responsible use look like day to day? And how do you get the best results at the lowest effective dose possible?Whether you just started, you're a few months in, or you're wondering why you're not seeing the results you expected — this episode is for you.IN THIS EPISODE, YOU'LL LEARN:Why you forget about food on a GLP-1 and why that feeling of relief is also where your responsibility beginsWhat the flat affect actually is, why it happens, and what it tells you about your doseWhy GLP-1 receptors live in the brain's reward center — and what that means for your dopamine, your drive, and your nervous systemThe difference between microdosing and the lowest effective dose (and why that distinction matters more than the label)FDA-approved dosing for semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — and where Melissa would actually startWhy digestion has to come first before or while on this medicationThe truth about blood sugar stability on a GLP-1 and why the medication doesn't do that work for youWhy women on GLP-1 are losing muscle without realizing it — and exactly what to do about itProgressive overload: what it actually means and why going through the motions isn't enoughWhy Melissa recommends Cronometer over MyFitnessPal for tracking on a GLP-1Hair loss — medication side effect or weight loss side effect? Melissa breaks down the differenceFatigue — why it's actually both, and what to do depending on which one it isWhy perimenopause symptoms can get louder on a GLP-1 and what's happening hormonallyHow to know if you're actually at a plateau (hint: four weeks is the threshold)What to do when you're at max dose and the scale still isn't movingHow long is it okay to stay on a GLP-1 — and what the long-term concerns actually areTIMESTAMPS:00:00 — Welcome back + recap of episode one 01:45 — What it actually feels like when you first start 03:30 — The flat affect and the dopamine loop 07:50 — Strength training as a natural dopamine regulator 10:00 — The lowest effective dose and what microdosing actually means 12:00 — Semaglutide dosing overview (Wegovy, Ozempic) 13:45 — Tirzepatide dosing overview (Zepbound, Mounjaro) 15:00 — How to advocate for a lower starting dose with your provider 16:00 — Melissa's personal experience: 1 mg tirzepatide for inflammation 23:30 — Making the medication work hard for you: the foundation 25:00 — Digestion first — why gut health matters before you start 26:30 — Blood sugar stability is your responsibility 29:00 — Protein first, always 31:00 — Why women on GLP-1 are losing muscle 33:30 — Progressive overload — what it actually looks like 35:00 — Track your food — why Cronometer and why it's non-negotiable 38:30 — Side effects: medication vs. weight loss (two different categories) 39:00 — Hair loss explained 40:50 — Fatigue explained 42:00 — Nausea, constipation, gut symptoms 42:45 — Perimenopause, hormonal shifts, estrogen dominance44:30 — How to know if you're actually at a plateau 48:00 — Max dose: what to do when you're there 48:30 — How long is it okay to stay on a GLP-51:00 — Download the GLP-1 Support Guide + closeRESOURCES:Download the GLP-1 Support Guide — everything you need to use this medication responsibly: workouts with logging space, protein meal plan, nutrition framework, and tracking tools. melissaeichwellness.com/GLP1guideBook a free consultation with Melissa — whether you're considering GLP-1, already on it, or wanting gut or hormone support while on it: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=6a0cb936104f4243883a46dfGut Healing Program or Complete Hormone Program: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=69fe864f4b36932a1ec4aba4Related episodes:Episode [#179]: GLP-1 Series, Part 1 — The Shame, the Gray Area, and Weight Loss Resistance: https://podcasts.apple.com/us/podcast/179-glp-1-for-midlife-women-where-to-begin-part-1-3/id1650475536?i=1000771142749DUTCH test series — perimenopause, weight loss resistance, and estrogen detox - https://podcasts.apple.com/us/podcast/176-perimenopause-weight-gain-and-the-dutch-test/id1650475536?i=1000767363294CONNECT WITH MELISSA:Instagram: @melissa_eich Website: melissaeichwellness.com Email: melissa@melissaeichwellness.comABOUT THE SHOW:Body-Led by Design is a podcast for women who are done guessing and ready to understand what's actually happening in their bodies. Hosted by Melissa Eich, registered nurse, hormone and nervous system coach, and somatic practitioner, each episode brings the real conversations from her practice so you can walk away more informed, more empowered, and a little less alone in what you're navigating.LEAVE A REVIEW:If this episode resonated with you, a five-star review means the world. It helps more women find this podcast and get the information they actually need.SEO KEYWORDS:GLP-1 side effects, semaglutide weight loss, tirzepatide lowest effective dose, microdosing GLP-1, hair loss on Ozempic, muscle loss GLP-1, weight loss plateau GLP-1, GLP-1 fatigue, Wegovy responsible use, perimenopause GLP-1, how long to stay on GLP-1, GLP-1 support women over 40

Nutritionist Leyla Muedin discusses research showing simple strength tests—grip strength and a five-rep sit-to-stand chair test—predict longevity in older women. In a University at Buffalo study of over 5,000 women ages 63–99 followed for eight years, stronger grip and faster chair-stand times were linked to lower mortality; every additional 7 kg of grip strength corresponded to a 12% reduction in death risk, and faster chair-stands were also associated with improved survival, even after adjusting for activity, cardiovascular fitness, and inflammation. She emphasizes prioritizing muscle-strengthening alongside aerobic exercise and suggests accessible resistance options (weights, bodyweight moves, or household items) with professional guidance as needed. She then cites UK Biobank data linking long-term statin use to declines in grip strength and appendicular lean mass, urging discussion with physicians and added vigilance, especially for those also using GLP-1 drugs that may reduce protein intake and muscle mass.

Can topical B12 help relieve itching?The types of doctors to avoidGetting back to basicsA case study of lavender oil helping to relieve itchingYou say you're dairy sensitive but you use whey protein. Please explain.What are your thoughts on a lactose relief patch that is on offer?

Welcome to the latest episode (June 2026) of Diabetes Core Update, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Update: Shah S, et al. "Food Coloring Additives and Incidence of Type 2 Diabetes in the NutriNet-Santé Prospective Cohort Diabetes Care. 2026;49(6):1067–1077. doi.org/10.2337/dc25-2727 Hespanhol L, et al. "Automated Insulin Delivery Systems in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis." Diabetes Care. 2026;49(6):1134–1143. doi.org/10.2337/dc25-2435 Tatum K, et al. "Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer." JAMA. Published Online: May 11, 2026 2026;9;(5):e2612133. doi:10.1001/jamanetworkopen.2026.12133 Winkler C, et al. "Screening Children for Early-Stage Type 1 Diabetes." JAMA. Published Online: May 21, 2026 doi:10.1001/jama.2026.6085 Würtz Yazdanfard P, Kosjerina V, Wood-Kurland H et al. "Effectiveness and Safety of Semaglutide in Type 1 Diabetes: A Danish Nationwide Cohort Study (2018–2024)" Lancet. Volume 66, 101716, July 2026. doi:10.1016/j.lanepe.2026.101716 Horn D, Aronne L, Wharton S et al. "Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial." Lancet. Published online May 12, 2026. doi:10.1016/S0140-6736(26)00656-2 Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, click here.

I am happy to connect with Dr. William Li today! He is a world-renowned physician, scientist, speaker, and author. He is known for leading the Angiogenesis Foundation, and his groundbreaking work has impacted more than 70 diseases. He is also a Ted-X speaker and the author of Eat to Beat Your Diet, one of my favorite books thus far this year.  Dr. Li's latest book is about what happens in the body, how it should operate, and the steps we can take to restore it to its hard-wired state. We dive into how body fat impacts our health, the role of metabolism throughout our lifetime, the differences between the three fat-impacting hormones, including leptin, adiponectin, and resistin, and gender differences. We speak about new drugs like Ozempic and Semaglutide, the role of brown fat, the impact of the microbiome and specific bacteria, and nutrition and lifestyle. IN THIS EPISODE YOU WILL LEARN: Why Dr. Li chose this time to write his latest book  Is 60 the new 20? The four stages of metabolism hardwired into each of us  How excess body fat derails metabolism, and how can we unleash our inner metabolism Why is it better to eat slowly? Why should we learn to respect and tame our fat instead of hating or fearing it? Dr. Li shares his views on new prescription drugs like Ozempic and Semaglutide. Interesting facts about body fat Changes that occur in our body fat distribution as we get older How can we help our bodies fight excess body fat, bring our inner metabolism to the surface, and reduce inflammation by being aware and mindful? Modern-day lifestyle choices and metabolic disease Dr. Li discusses the interplay between the gut microbiome and metabolism, as well as the role of Akkermansia.  Some everyday foods contain natural chemicals that can activate our body's defenses, tame metabolism, and fight body fat. BIO William W. Li, MD, is an internationally renowned physician, scientist, and New York Times bestselling author of the forthcoming book “Eat to Beat Your Diet: Burn Fat, Heal Your Metabolism, Live Longer”. His groundbreaking work has led to the development of more than 30 new medical treatments and impacts care for more than 70 diseases, including cancer, diabetes, blindness, heart disease, and obesity. His TED Talk, “Can We Eat to Starve Cancer?” has garnered more than 11 million views. Dr. Li has appeared on Good Morning America, CNN, CNBC, LIVE with Kelly and Ryan, and the Rachael Ray Show, and he has been featured in USA Today, Time Magazine, The Atlantic, and O Magazine. He is the president and medical director of the Angiogenesis Foundation. Connect with Cynthia Thurlow Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com  Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow.  Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line Connect with Dr. William Li On his⁠ website⁠ Social media: @DrWilliamLi Dr. William Li's latest book, ⁠Eat to Beat Your Diet: Burn Fat, Heal Your Metabolism, and Live Longer⁠ is available from most bookstores.

Highlights from Dr. Hoffman's Scandinavian tripShould I eliminate the nightshade family of foods from my diet?My friend has been experiencing acid reflux since using a reverse osmosis water filtration system

Book a free consultation call with Robert Sikes to break through your keto or low carb plateau right here: https://www.ketobodybuilding.com/callSurviving childhood morbid obesity and a fifteen year meth addiction takes total metabolic repair. In episode 886 of the Savage Perspective Podcast, host Robert Sikes sits down with Elaina Wang to share a powerful story of survival and deep health recovery. This discussion reveals how severe insulin resistance and bad food rules created a massive drug habit just to feel energy. Getting clean from drugs was brutal, but finding the keto diet and reversing type two diabetes naturally changed her entire life. You will learn exactly how real nutrition, heavy weight lifting, and targeted peptides can heal your brain, stop cravings, and fix chronic pain after years of severe trauma and addiction.Elaina's Hack Your Health Coaching: https://hackyourhealthcoaching.com/elaina-wangElaina's FB: https://www.facebook.com/KetoWang/Get Keto Brick: https://www.ketobrick.com/Subscribe to the podcast: https://open.spotify.com/show/42cjJssghqD01bdWBxRYEg?si=1XYKmPXmR4eKw2O9gGCEuQChapters0:00 - How I Survived Childhood Obesity & Severe Insulin Resistance1:09 - Why I Started Meth: The Shocking Truth About Energy & Fatigue2:01 - The Food Pyramid Myth: How Government Guidelines Fueled Addiction3:47 - Unbreakable Confidence: How to Build Self-Esteem When Overweight6:14 - The "Fat Meth Addict": Why Stimulants Couldn't Fix Type 2 Diabetes8:17 - Meth vs Cocaine: How Drugs Hijack Brain Dopamine & Sugar Cravings11:08 - The Secret Life of a Functional Addict: Survival Tactics & Thefts13:36 - Toxic Relationships: Navigating Co-Dependency & Addiction Relapse17:03 - The Turning Point: Dodging the Cops & Deciding to Get Clean20:43 - Type 2 Diabetes Diagnosis at 24: Ignoring the Ultimate Warning Sign21:10 - Quitting Meth Cold Turkey: The Brutal Reality of Early Sobriety25:22 - Blood Sugar at 426: Why I Refused Insulin Due to Addiction Fears27:08 - Reversing Type 2 Diabetes Naturally with the Keto Diet28:24 - Keto & Neuroplasticity: The Ultimate Biohack for Addiction Recovery30:02 - Losing 80 Lbs Fast: Do Cigarettes Spike Your Blood Sugar?34:00 - Becoming a Keto Coach: The Evolution of Low-Carb & Carnivore Diets36:10 - Healing Trauma vs. Trauma Bonding: The Missing Link in Weight Loss41:17 - BPC-157 & TB-500: Can Peptides Cure Chronic Pain & Bursitis?45:13 - GLP-1 for Addiction: The Unbelievable Cure for Alcoholism & OCD49:02 - Semaglutide vs Tirzepatide: Which GLP Weight Loss Peptide is Best?51:49 - The Dark Side of Ozempic: Who Should NEVER Take GLP Peptides53:31 - 155 Lb Weight Loss Surgery: Is Medical Tourism in Tijuana Safe?57:11 - Tummy Tuck Complications: Hematomas, Wound Vacs & Honest Recovery1:01:01 - "Am I Too Old to Get Healthy?" The Ultimate Mindset Shift for Men & Women1:05:26 - Where to Find Elaina Wang: Coaching, Biohacking & Future Events